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FOREWORD 
 
The Trent  Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Purchasing 
Authorities Chief Executives (PACE) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterDEC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development, The Scottish Health Purchasing Information Centre 
(SHPIC) and The University of Birmingham Department of Public Health and Epidemiology. 
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EXECUTIVE SUMMARY 
 
 Schizophrenia is a chronic relapsing psychotic disorder where the outcome is variable.  It 
has an annual incidence of approximately two per 10,000 population per annum. More 
than 50% of patients may develop a chronic illness giving period prevalence rates of 4 
per 1,000 over six months for the 16-64 year old population at risk. 
 Acute (positive) symptoms include: hallucinations, delusions and thought disorder. 
Chronic or deficit states are characterised by negative symptoms including: social 
withdrawal, blunting of affect and lack of motivation. 
 Using a population of 500,000 as a ‘typical’ district, evidence suggests that there may be 
up to 64 new patients a year diagnosed with this condition.  Likewise, in any one six 
month period, it might be expected that there are some 1,200 -1,400 patients with active 
schizophrenia.  There exists a growing body of evidence to suggest that the true burden  
of schizophrenia, in terms of relapse rates and hospitalisation rates, is more severe than 
has previously been generally accepted. 
 Studies estimate the overall UK cost burden of schizophrenia, including the direct and 
indirect costs, at £2.6 billion per annum. Recent reviews have estimated the UK direct 
costs of schizophrenia to lie in a range somewhere between £396 million - £714 million 
per annum. Hospitalisation represents around 90-95% of all direct costs related to 
schizophrenia, with drug costs at 2% representing a much smaller proportion of total 
expenditure. 
 The major negative points of conventional drugs are seen to be the high incidence of 
associated extrapyramidal side-effects and the fact that there is little observed effect on 
the negative symptoms of schizophrenia. Thus (in respect of conventional drugs): 
 30-40% of patients do not respond during an acute episode; 
 they are largely ineffective against the negative symptoms of schizophrenia; 
 they are associated with medication compliance problems; 
 up to 40% of patients will relapse within two years despite prophylaxis; 
 up to 75% of patients will experience extrapyramidal side-effects (EPSE) 
 5% of patients per year will develop tardive dyskinesia. 
 The newer ‘atypical’ antipsychotics are now becoming increasingly prescribed for certain 
schizophrenic patients and represent a real alternative to conventional drugs. Available 
clinical evidence on the newer ‘atypical’ drugs shows that they: 
 are generally better tolerated than conventional drug therapy; 
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 have a lower observed rate of EPSE; 
 are at least as clinically effective as conventional drug therapy;  
 have the potential to influence negative symptoms; 
 represent a significant increase in pure drug costs. 
 However, there is little long-term trial evidence related to the newer ‘atypical’ drugs and 
the projection of resource impacts remains difficult to quantify. 
 There is also a lack of direct trial comparisons of these drugs against each other, with 
most trials comparing with conventional drugs, such as, haloperidol. This means that 
making comparative statements about these drugs is difficult. 
 Up to 70% of schizophrenic patients may be suitable for treatment with ‘atypical’ 
antipsychotics, given that 30% of patients achieve a maintained response on 
conventional drugs. 
 The marginal drug costs for a ‘typical’ district are estimated at between £520,000 (if 
given to 20% of all schizophrenic patients) and £1,820,000 (if given to 70% of all 
schizophrenic patients). 
 The cost-effectiveness argument for ‘atypicals’ remains unproven, although, in the case 
of clozapine, there does appear to be good evidence showing sufficient cost savings 
from in-patient and other costs to off-set the high direct costs of the drug. Many of the 
published cost-effectiveness studies are still based on the short-term evidence base.  
 There is a need for continued randomised controlled trials (RCTs) of newer ‘atypical’ 
drugs, with more evidence of comparative efficacy and cost-effectiveness. Also a longer 
time period is required in the follow-up of patients. 
 The modelling of cost-effectiveness may provide a framework within which trial data can 
be combined with clinical experience to consider the longer-term projected impact of 
these drugs. A process for such an exercise is discussed in the Guidance Note. 
 Future prescribing of the newer ‘atypicals’ must be accompanied by a rigorous process 
of patient follow-up and monitoring, possibly based around a regional patient database. 
This would allow further evaluation of clinical impact, resource use and cost-
effectiveness in real practice alongside any such trials.  
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1.  INTRODUCTION 
 
1.1  General Overview 
 
Schizophrenia is one of the major psychiatric disorders, characterised by the presence of 
psychotic symptoms, thought disorders and severe disturbances of psychosocial 
functioning.  
 
The illness typically presents in early adult life (median 25 years male/28 years female) and 
can have a devastating effect upon the lives of individuals affected by it, including both the 
sufferers themselves and their families and network of supporting carers.  
 
There is no known cure for schizophrenia and all treatments are aimed at improving 
symptoms and delaying or preventing relapse.  
 
Until 1989, pharmacological treatments were based on the antipsychotic (antidopaminergic) 
drugs: chlorpromazine, haloperidol and depot equivalents. These drugs come from a 
classification or drug group now commonly referred to as the conventional antipsychotics. 
The conventional drugs first appeared on the market in the 1950s and represented the first 
major pharmacological breakthrough in the treatment of schizophrenia. However, whilst 
some patients respond well to conventional drug treatment, a significant proportion remain 
either refractory to any clinical effect or cannot tolerate the associated extrapyramidal side-
effects (EPSE), which are predominantly drug related.  
 
With the initial development and later re-introduction of the antipsychotic drug clozapine,  
previously withdrawn due to its potential side-effects, and the subsequent introduction of 
other newer/novel antipsychotic compounds, there now exists a potential opportunity to 
improve significantly the quality of life of patients suffering from schizophrenia. This is 
mainly due to the claims of reduced levels of observed side-effects experienced by patients 
with the newer (‘atypical’) antipsychotics, in particular, those effects related to EPSE, and 
also their potential to influence both the positive and the negative symptoms of 
schizophrenia. 
 
Whilst clozapine itself is restricted to treatment resistant patients, due to the recognised risk 
of agranulocytosis (a lowering of the white blood cell count), the other newer ‘atypical’ drugs 
have no such licensing restrictions with regard to their use. Therefore, the newer drugs are 
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generally considered by clinicians as an appropriate first-line treatment option for 
schizophrenia alongside the existing conventional drugs. There is also an increasing level of 
expectation for ‘atypical’ antipsychotics in the management of schizophrenic patients who 
are proved to be treatment-resistant to conventional drug therapy, although evidence for 
their clinical effectiveness in these patients is limited. Clozapine remains the only proven 
‘atypical’ in treatment-refractory patients. 
 
The currently available licensed ‘atypical’ antipsychotics include: 
 
 Clozapine   - (Clozaril    1990)  licensed for treatment-resistance patients only 
 Risperidone  - (Risperdal 1993) 
 Olanzapine  - (Zyprexa   1996) 
 Sertindol  - (Serdolect 1996) 
 Quetiapine - (Seroquel  1997) the most recent addition to the list 
 
Other drugs in the late stages of development include: 
 
 Ziprasadone  
 Zotepin   
 Amisulpride. 
 
With further antipsychotic drugs now in development, and the focus of current ongoing 
clinical trials, this list of licensed ‘atypical’ antipsychotics is sure to increase, providing 
clinicians with a range of different and alternative treatment options. This is especially the 
case with the ‘atypicals’ as each drug has its own specific mechanism of action and 
underlying pharmacological basis. In pure drug cost terms, this increase in availability of 
newer ‘atypicals’ has an obvious financial implication on health authorities, as they represent 
a significantly more expensive treatment regimen than conventional drugs when considered 
on a dose equivalent basis. 
 
There is great variation between health districts in the extent to which the newer ‘atypical’ 
antipsychotic drugs are currently used. This variation may have resulted from either an 
intentional policy by health authority and/or provider, or may have arisen as a result of 
unplanned clinical activity. There is now a great need to provide advice about effectiveness,  
costs and benefits, and possible models for introducing ‘atypical’ antipsychotic drugs and so 
to assist in the development of rational and consistent policies for the provision of these 
drugs on the basis of need.    
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The purpose of this Guidance Note is both to consider the current state of evidence for the 
clinical efficacy of the newer antipsychotics and to highlight and suggest the levels of cost-
effectiveness associated with their use. The Note recommends to purchasers the most 
suitable place for newer antipsychotics in the treatment pathways for schizophrenia. 
 
1.2  Incidence and Prevalence 
 
Schizophrenia is not a common illness having an annual incidence of approximately 2 per 
10,000 population per annum.
1,2,3
 This is expressed in terms of the ‘at risk’ population, most 
commonly defined as the 16-64 years age group. In terms of overall risk, the illness has a 
lifetime prevalence in the range of 6-12 per 1,000 population ‘at risk’ and is often 
approximated at a level of 10 per 1,000,  although there is some evidence that this may be 
declining.
4
   
 
However, more than 50% of patients may develop a chronic illness giving period prevalence 
rates of 4 per 1,000 over six months for the 16-64 year old population ‘at risk’. The average 
GP is expected to be in direct contact and providing care for around 10-20 schizophrenic 
patients;
1
 this obviously depends on the location and social background of individual 
practices. 
 
Data from general practice suggest that the annual incidence of what the GP considers to 
be schizophrenia is higher than the incidence rate ascertained from secondary care 
studies.
5
 These discrepancies in reported and recorded cases of schizophrenia highlight the 
difficulty in making consistent diagnoses, hence the need for operationally defined 
diagnostic criteria. A significant proportion of those presenting to primary care are of a 
transient nature and, therefore, would not meet these strictly defined criteria, but represent a 
broader range of ‘psychotic’ disorders. Therefore, incidence rates will be expected to vary 
dependent on the degree of stringency used. 
 
1.3  Positive and Negative Symptoms 
 
Schizophrenia is a chronic relapsing psychotic disorder although the outcome is variable. It 
is characterised in the early stages by acute (positive) symptoms including: hallucinations, 
delusions and thought disorder. In a significant  number of patients over time, there is the 
development of the chronic or deficit state characterised by negative symptoms, including; 
social withdrawal, blunting of affect and lack of motivation.  
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The following table details the typical profile of symptoms associated with schizophrenia. 
 
Table 1 Positive and Negative Symptoms 
Positive Symptoms Negative Symptoms 
 hallucinations  withdrawal from social contact 
 delusions  blunted emotions 
 bizarre behaviour  lack of motivation 
 hostility  inability to experience pleasure 
 thought disorder  slowness of movement and thought 
 
It is important to recognise that the negative symptoms of schizophrenia can have both 
‘primary’ and ‘secondary’ causes, which are often difficult to identify and separate, in both 
the environments of clinical trial and clinical practice alike. 
 
Primary Symptoms  Primary negative symptoms are those which are directly related 
to the illness itself and have a clinical basis. 
 
Secondary Symptoms Secondary negative symptoms are largely thought to be a direct 
consequence and effect of conventional medication. They are 
also thought to manifest themselves as a consequence or 
‘reflection’ of the positive symptoms of the illness. 
 
Clearly, the reality here is that patients are likely to have a mix of both primary and 
secondary negative symptoms.  
 
Many of the newer antipsychotics show some suggestion of clinical effect and improvement 
in negative symptoms, even in those clinical trials conducted over a relatively short time 
period of 6-12 weeks. However, there are still remaining questions and clinical debate as to 
whether this reduction is : 
 
 due to the removal of conventional drugs from treatment; 
  
 due to a reduction in positive symptoms and hence a result of the clinical efficacy of 
‘atypicals’. 
 
1.4  Outcome Measurement and Psychiatric Rating Scales  
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There are four key tools of measurement commonly used in the quantification of treatment 
efficacy in schizophrenia. These assessment tools are based on both the positive and 
negative symptoms of schizophrenia, both in isolation and also as combined symptomatic 
measures. There is no overall accepted standard in the measurement and assessment of 
clinical response to treatment alternatives in schizophrenia. All the scales are used to some 
degree or other in clinical trials and their assessments:  
 
 Positive and Negative Syndrome Scale (PANSS) (Kay et al. 1987)
6
 
 Brief Psychiatric Rating Scale (BPRS) (Overall JE et al. 1962)
7
 
 Clinical and Global Impression (CGI) (Guy 1976)
8
 
 Scale for the Assessment of Negative Symptoms (SANS) (Andreasen 1982)
9
 
  
1.5  Pharmacology of Antipsychotic Drugs 
 
There is no cure for schizophrenia and current pharmacological treatment aims to reduce 
and/or control psychotic symptoms, improve functioning and delay or prevent recurrent 
episodes.  
 
Conventional antipsychotics are dopamine (D2) antagonists and have a number of 
drawbacks. These include serious side-effects, particularly extrapyramidal including tardive 
dyskinesia; also an estimated 30% of patients remain unresponsive and their psychotic 
symptoms persist. Conventional drugs are also ineffective against the negative symptoms of 
schizophrenia and do little to prevent a chronic deficit state developing. This combination of 
side-effects and a failure to tackle negative symptoms leads to a recognised poor quality of 
life for patients, even when in a maintained state. 
 
While the aetiology of schizophrenia remains elusive, there are well described genetic links 
and some evidence for possible environmental factors. The dopamine hypothesis is widely 
accepted - it states simply that schizophrenia is caused by an overactivity of the 
dopaminergic mesolimbic and mesocortical neurotransmitter systems. There is, however, 
little direct evidence for this from neuropharmacological and neuropathological studies. 
Furthermore, even if this hypothesis is correct, it does not explain the primary aetiological 
factor. 
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The dopamine hypothesis evolved simply from the observation that the conventional 
antipsychotic drugs, based on dopamine antagonists, were found to alleviate psychotic 
symptoms. Their mechanism of action was assumed to be via this dopaminergic blockade. 
They also block other neurotransmitter systems including, serotonin, noradrenaline, 
acetylcholine and histamine.  
 
There are three main dopaminergic tracts centrally: 
 
 mesolimbic and mesocortical (brain stem to temporal lobe); 
 nigrostriatal (brain stem to basal ganglia); 
 hypothalamo-pituitary.  
 
It is thought that, while the mesolimbic system is central to the pathology of schizophrenia, 
conventional drugs unfortunately also block all dopamine areas and, thus, cause significant 
side-effects, extrapyramidal in the case of nigrostriatal blockade and hyperprolactinaemia 
from the effect on the hypothalamus. There are only minor variations between the different 
classes of conventional antipsychotics, thus, overall efficacy and incidence of side-effects is 
roughly equivalent. 
 
With increasing knowledge of dopaminergic neuronal systems, and further elucidation of 
other neurotransmitter systems, which either act independently or through interaction with 
dopamine systems in the pathophysiology of schizophrenia, newer compounds have been 
developed. Several dopamine receptor sub-types have now been identified - D3,  D4 and D5. 
Their anatomical distribution varies, thus opening up the theoretical possibility of greater 
drug specificity of action. The D4 receptor also shows genetic polymorphism and the variants 
differ in their response to antagonists. 
 
Serotonin (or 5HT) has also emerged as a neurotransmitter of great importance for a 
number of reasons:  
  
 5HT interacts with dopaminergic neuronal systems in both brain stem and cortex; 
 clozapine is a potent 5HT antagonist, a possible explanation for its antipsychotic 
properties; 
 certain 5HT agonists cause psychotic symptoms.  
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Thus, there has been a proliferation of new ‘atypical’ antipsychotic compounds, which use 
these new findings in an attempt to be more efficacious and better tolerated. The potential 
benefits of a more targeted and selective drug therapy can be clearly seen: improved 
compliance; reduction in side-effects; and better management of the  illness. 
 
There are a number of different categories of ‘atypical’ antipsychotic compounds: 
 
 dopamine autoreceptor agonists (that have questionable antipsychotic activity); 
 5HT antagonists; 
 mixed compounds that have both dopamine and 5HT antagonistic properties.  
 
It is important to bear in mind that these new drugs also block other neurotransmitter 
systems to varying degrees therefore, and, are not totally free of side-effects.  
 
New compounds now available for treatment include clozapine, risperidone, sertindole, 
olanzapine and quetiapine. Three further compounds are completing phase III trials and will 
soon be available: ziprasadone, amisulpride and zotepine. 
 
1.6  Standard Definition of ‘Atypical’ Antipsychotics 
 
In considering the definition and categorisation of ‘atypicals’, it is  important first to clarify 
any confusion over the use and meaning of the two terms antipsychotic and neuroleptic, as 
they are commonly and inappropriately interchanged. The conventional drugs have 
traditionally been referred to as ‘neuroleptic’ as a direct description of their well documented 
neurological side-effects, in particular EPSE. As the newer drugs are observed to have a 
much lower incidence of EPSE, it is technically inaccurate to refer to them as ‘neuroleptic’ 
and the term ‘antipsychotic’ is commonly used. 
 
Although the term ‘atypical’ has been widely used to date in labelling this group of newer 
antipsychotics, it is difficult to provide a clear and exact definition as to what truly represents 
a true atypical drug. Indeed, all these drugs have their own individual mechanisms of action 
and pharmacology and there is an increasing movement away from assigning an overall 
group name. However, it is possible to draw some overarching common features of the 
newer drugs for schizophrenia.  
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To clarify the terminology, a conventional ‘antipsychotic’ or ‘neuroleptic’ satisfies the 
following criteria according to Delay and Deniker (1957)
10
: 
 
 ‘the antipsychotic effect was not due to sedation; 
 it caused a decrease in psychomotor activity; 
 it induced EPSE and catalepsy’. 
 
An ‘atypical’ or newer compound is less clearly defined, but would satisfy the following 
criteria: 
 
 the antipsychotic effect was not due to sedation; 
 causes less or no acute extrapyramidal symptoms (i.e. motor side-effects);  
 causes little or no tardive dyskinesia (TD) when compared to typical drugs; 
 does not produce sustained elevation in prolactin (i.e. a hormone which causes 
gynaecomastia  - breast enlargement) above the normal range. 
 
In addition, ‘atypical’ compounds could also be considered to: 
 
 alleviate positive symptoms (i.e. delusions, hallucinations) as well as negative symptoms    
(i.e. blunted emotion, apathy, social withdrawal); 
 alleviate neurocognitive deficits (i.e. problems in attention and information processing). 
  
1.7  Prognosis and Mortality 
 
In terms of an overall prognosis for patients suffering from schizophrenia, it has been 
assumed historically that, as a general approximation, one third of patients with diagnosed 
schizophrenia will return to a largely symptom-free life, whilst one third will remain troubled 
by symptoms, but will remain independent within the community, and up to one third will 
have a longer-term chronic course with more serious disruption of normal social functioning 
over time.  
 
However, more sophisticated cohort studies (designed specifically to uncover the true profile 
of schizophrenia) now indicate that there are more chronic patients than previously believed. 
 
A recent review of schizophrenia reported data from a number of different cohort studies.
11
 
The largest and most notable of these studies suggested that in reality up to 82% of patients 
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will actually experience a relapse of their illness, implying, therefore, that only 18% of 
patients would return to an episode-free life.
12
 This compares with the higher estimate of a 
third of patients experiencing no further relapse, as generally quoted. The study also 
suggests that 75% of patients actually will have at least one hospital re-admission due to 
relapse.  
 
An earlier study, which included all schizophrenic patients, also found that only 32% of 
schizophrenic patients would achieve an outcome which could be considered to be relatively 
mild.
13
  When restricted to those who suffer only a single episode, the proportion of patients 
with a mild outcome reduces to 16% of the total schizophrenic population.  
 
Studies of patients who have repeated relapse episodes of schizophrenia  report that 43% 
of patients experience longer-term enduring symptoms, associated with a lack of full 
remission and representing a chronic state. This compares with the historical view of 33% of 
patients experiencing a chronic illness state. Furthermore, studies also show that 9% of 
patients are expected to suffer a life long lasting impairment related to schizophrenia.  
 
Therefore, there now exists a body of strong evidence both to suggest and support the view 
that the true burden and course of schizophrenia, in terms of relapse rates and 
hospitalisation rates, is more severe than has been previously generally accepted.  
 
The true profile and prognosis of schizophrenic patients is likely to lie somewhere in the 
ranges suggested below, with the historical view representing  the lowest estimate of those 
arriving at a chronic state and likely to be involved in hospitalisation and long-term clinical 
care. 
 
 Single acute episode  10-20% 
 Multiple acute episode   30-60% 
 Chronic long-term state  30-50% 
  
It is also widely recognised that schizophrenic patients have a much increased risk of 
suicide than the general population. Up to 10% of patients with schizophrenia will eventually 
commit suicide. A recently reported cohort study claimed that the risk of suicide increases 
by a factor of 20x for men and 3x for women.
14
 
 
In terms of general morbidity, it is also widely accepted and recognised that schizophrenic 
patients have much reduced levels of good physical health. This reflects both patients’ lack 
  13 
of access to primary care based services and also a lack of an ability to assimilate and act 
on general health care advice.
14,15
  
 
Another important issue is the level of schizophrenic patients who are currently cared for in 
forensic institutions. In a recent prevalence study of prisoners a 5% point prevalence rate 
was noted for psychosis.
16
 This raises a number of questions relating to the availability of 
healthcare services and appropriateness of the setting of care. This level of psychosis within 
prisons has obvious resource consequences and presents a significant element of societal 
cost. This raises the question of whether an improved level of treatment/maintenance of 
schizophrenia within the criminal system would result in less need for secure 
accommodation.  It is not within the scope of this Guidance Note to explore this particular 
issue, but the point needs highlighting as an area of expenditure, related directly to 
schizophrenia, where there is potential for both cost reduction and patient benefits, given 
more appropriate and clinically effective treatment options. 
 
Overall, the picture of schizophrenia is one of an illness which is probably more chronic than 
has previously been appreciated. The advantages of achieving an early recognition and 
appropriate choice of treatment for schizophrenia can be summarised: 
 
 reduction in the level and frequency of further relapse; 
 minimisation of the positive aspects of the illness; 
 limitation of  the associated anxiety and depression; 
 limitation of the cognitive deterioration associated with the illness; 
 limitation to the loss of social skills and of family/social support systems; and 
 reduction in the opportunity for loss of personal self care skills. 
  
1.8  Cost Burden and Resource Implications 
 
Without doubt, schizophrenia represents a significant cost burden to the NHS, via the direct 
costs of drugs and supportive care, and to wider society, with implications in terms of lost 
employment opportunity, family support and the provision of community-based services. 
 
Recent reviews have estimated the direct costs of schizophrenia to lie in a range 
somewhere between £396 million - £714 million per annum.
11,17
 Most of this estimated direct 
cost is related directly to the costs of in-patient care and hospitalisation. Drug costs 
represent a much smaller proportion of total expenditure related to schizophrenia. 
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The following table breaks down the NHS direct costs, which relate directly to schizophrenia, 
and expresses them as a proportion of total expenditure. The figures are based on NHS 
data for 1992/93 and are taken from the Knapp review of schizophrenia costs.
11
 
Table 2 Direct Costs Related to Schizophrenia 
Expenditure on 
schizophrenic patients: 
Category 
Cost  Percentage of individual 
budget within category 
 
In-patient   £652.2m  5.37% 
Out-patient  £0.9m  0.04% 
Primary Care  £1.8m  0.05% 
Drugs  £32.4m  1.06% 
Community Care  £26.2m  0.9% 
Social Services  £96.5m  1.8% 
TOTAL EXPENDITURE  £810.0m  2.76% 
 
The table presents the proportion of each individual NHS and Social Services budget as well 
as an aggregated total proportion of NHS and Social Services expenditure of 2.76% 
 
Not surprisingly, the biggest impact of schizophrenia, in terms of both cost and proportion, 
lies in in-patient care. Using these figures as a cost base, the in-patient activity represents 
around 90-95% of the cost of schizophrenia, with drugs accounting for 1-2%. Therefore, the 
biggest potential for resource savings in the treatment and care of schizophrenic patients 
lies in the provision of in-patient care rather than with direct pharmaceutical costs. 
 
The study estimates the overall cost burden of schizophrenia, including the direct and 
indirect costs, at £2.6 billion per annum. 
 
In contrast, an alternative study, calculating the NHS and social care cost of schizophrenia, 
reports the total direct costs of schizophrenia in the UK as £397m per annum (1.6% of the 
total health care budget).
18
  Hospital and community-based residential care accounted for 
75% of these costs with drugs still representing only 5% of the overall total cost. The 
conservative estimate of indirect costs amounted to £1.7 billion per annum, this being based 
on a calculation of expected lost production and unemployment costs. 
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The study further stated that 97% of these direct costs were incurred by less than 50% of 
the schizophrenic patients. This estimate was made using published groupings which divide 
the schizophrenic patients into five outcome groups.
19
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Table 3 Prudo & Blum 1987 - Schizophrenic Patient Classification 
 Patient Group Definition  
Group 1 Only a single episode of schizophrenia, with an average duration of 22 weeks 
Group 2 Episodes of major disorder lasting up to 1 year 
Group 3 Episodes for 1-2.5 years 
Group 4a Episodes > 2.5 years, requiring predominantly community based care 
Group 4b Episodes > 2.5 years, requiring long-term care in either hospital or community 
 
The mean annual direct cost per patient was estimated at £2,138 and was accounted for by 
items listed in table 4. Whilst this is useful information, it is important to appreciate that 
schizophrenic patients have a wide range of different symptoms and outcomes as the illness 
is extremely heterogeneous. Thus, the average cost varies enormously and is very much  
dependent on the outcome profile of the patient. Using the patient groupings, the cost per 
patient per annum varies from £1,700 in patients with a single episode of less than six 
months’ duration (19% of all patients) to £316,000 in patients in long-term residential care 
(20% of all patients). It becomes self evident that the opportunity to reduce costs is greater 
for those patients at the severe end of the spectrum. 
 
Table 4 Breakdown of Mean Annual Direct Cost of Schizophrenia 1991 prices 
Item Cost  % 
Hospitals/residential care  £1,580  74% 
Out-patients (OP)  £72  3% 
Day-care  £292  14% 
Community visits  £81  4% 
Depot/other OP visits  £41  2% 
Other drugs  £72  3% 
Total Mean Cost  £2,138  100% 
   
1.9  Scale of the Problem in a ‘Typical’ District 
 
Using a population of 500,000 as a ‘typical’ district, evidence suggests that there may be up 
to 64 new patients a year diagnosed with this condition. This estimate is based on the 2 per 
10,000 annual incidence rate and an estimated ‘at risk’ population, 16-64 years old, of 
400,000.
20
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A recent review in Nottingham revealed an incidence of schizophrenia of around 30-40 
patients per annum for a population ‘at risk’ of around 400,000. This was defined as true 
ICD10-F20 schizophrenia; the initial level of diagnosis was 168 new cases and included 
broader definitions.
4
 
 
In any one six month period, it might be expected that there are some 1,200 -1,400 patients 
with active schizophrenia (1,300 based on a 4 per 1,000 average period prevalence rate), 
although these patients may not necessarily be in regular contact with psychiatric services. 
A point audit of schizophrenic patients in Nottingham estimated between 1,200 - 1,300 
patients in contact with existing services. A lifetime risk of 1% means that, within the ‘at risk' 
population, 4,000 persons may experience, or have been previously given, a diagnosis of 
schizophrenia. 
 
Of patients in contact with services, 13% may be in-patients at any one point in time.
21
 The 
rate of in-patient activity, however, can vary greatly across districts and an alternative value 
of 28% was also reported from a rural area study.
22
 This variation may reflect many different 
influences including the extent of social services or other residential provision, differing 
clinical practice, institutional closure, as well as actual need based on the socio-
demographic mix of the host population. There is a general consensus that the current 
balance in the provision of in-patient long-stay beds is inappropriate, with many chronic 
long-term patients occupying acute unit beds. 
 
Recent studies have suggested that this level of recorded schizophrenia may be declining, 
particularly in the more pure schizophrenia diagnosis (ICD10-F20). However, overall the 
level of psychotic illness appears constant and it remains to be seen whether this is a valid 
finding or simply a reflection of changes in diagnostic behaviour.
4
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2. ‘ATYPICAL’ ANTIPSYCHOTICS IN THE TREATMENT OF 
SCHIZOPHRENIA: SUMMARY OF EVIDENCE OF EFFECTIVENESS 
 
In evaluating the quality and direction of evidence for the use of newer antipsychotics in the 
treatment of schizophrenia, it helps first to review the case for conventional drugs and then 
to consider the newer ‘atypical’ antipsychotics in further detail. 
 
2.1  Clinical Effectiveness of Conventional Drug Therapy 
 
Effective psychopharmacological interventions for schizophrenia were introduced in the 
early 1950s with the discovery of chlorpromazine. Within a very short period of time this 
class of drugs became widely prescribed. Drugs such as chlorpromazine, haloperidol and 
the depot medications, flupenthixol and haldol, have been regarded previously by clinicians 
as the optimum pharmacological treatments for schizophrenia.  
 
The efficacy of conventional drugs is now well established, in both reducing the positive 
symptoms of schizophrenia and lowering the longer-term relapse rates. There exists a wide 
range of published trials designed to evaluate the effectiveness of conventional drugs.  
 
These trials tend to vary in overall quality and are generally considered to be dated and 
small in terms of their overall trial design, however, their key messages are not thought to 
be in any doubt.
23
 
 
The following assessment of efficacy is drawn from this body of evidence and is well 
replicated and not considered clinically controversial.  
 
2.1.1  Response Rates 
 
Numerous studies have demonstrated the efficacy of conventional drugs in alleviating the 
positive symptoms of schizophrenia and in the prevention of relapse over the longer-term. 
Only 60-70% of patients are expected to show a clinical response to conventional 
antipsychotics in an acute episode.
23
 However, the proportion who can be maintained 
effectively on conventional drugs remains at a much lower level (approx. 30%) due to 
adverse effects and treatment tolerability.  
 
Importantly, the available published studies show that conventional drugs have no significant 
effect on the negative symptoms of schizophrenia.
24
 The functional impairment in social and 
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vocational activities that occurs in schizophrenia is not necessarily diminished by 
conventional antipsychotics, even when positive symptoms are alleviated.
25
 
 
It is possible to identify poor prognosis non-responders early; as being those with a long 
prodromal illness and untreated psychosis and patients with structural brain 
abnormalities.
26,27
 
 
2.1.2  Relapse Rates 
 
A review of conventional drugs analysed 24 studies, which considered relapse as one of the 
key outcome measures.
28
 It was concluded that 65% of patients relapse without medication, 
but 30% relapse even when on conventional medication. Another report, reviewing studies 
lasting between 10 and 24 months, noted a similar finding with a 8-40% relapse rate for 
patients on medication.
29
 Up to 14% of first episode patients fail to respond to conventional 
medication.
30
 
 
Medication non-compliance appears to be a common factor in relapsed schizophrenic 
patients. Compliance problems are a major difficulty with conventional drugs and it is 
estimated that more than half of schizophrenic patients do not take their medication 
correctly.
31
 
 
2.1.3  Tolerability and Side-Effects of Conventional Drug Treatment 
 
A major group of observed side-effects related directly to conventional drug therapy are the 
EPSE. 
 
EPSE are unpleasant, stigmatising and common, and are seen by clinicians and patients 
alike as a major drawback to conventional antipsychotics. Up to 75% experience EPSE as a 
result of their treatment for schizophrenia.
32
  EPSE represent a significant reason for non-
compliance with treatment and, hence, subsequent relapse. The following table summarises 
the four key EPSE symptoms and presents them in the order of chronological risk. 
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Table 5 Extrapyramidal Side-effects 
Side Effect Description 
Tardive Dyskinesia 
 
(Months/Years) 
This is perceived to be the most serious of the EPSE. It is 
characterised by a series of involuntary movements of the mouth, 
tongue and face. This has obvious consequences in terms of 
patient acceptance in the community and presents a real barrier to 
social interaction. Unfortunately, there is a significant proportion of 
patients for whom this side-effect will remain a permanent feature 
even after reducing their medication. 
Akathisia 
 
(Weeks/Months) 
This is characterised by a restless feeling and causes patients to 
be continuously moving. It can be misinterpreted as a reflection of 
the illness itself, rather than drug-related, leading to an increase in 
medication. 
Parkinsonian 
Symptoms 
 
(Days/Weeks) 
These are side-effects which present in the same form as the 
symptoms of Parkinsonism. They cover tremors, muscle rigidity 
and an overall slowing of patients’ movements. The walking style 
of patients is invariably seen as a shuffling gait. The effects are 
relatively quick to manifest themselves often after only a few days 
or weeks of treatment. 
Acute Dystonic 
Reactions 
 
(Hours/Days) 
These effects present as a series of involuntary muscle 
contractions, typically involving the neck and head. The effects are 
extremely distressing to patients who remain conscious and very 
much aware of them. These side-effects appear soon after 
commencing drug treatment and are dose related.  
 
Tardive dyskinesia (TD), the most severe and debilitating EPSE, increases by 5% per year 
in patients on long-term medication. TD is largely untreatable and there have been lawsuits 
against psychiatrists in the USA by patients who developed TD when alternative drugs were 
available. TD represents a significant quality of life issue with schizophrenic patients on 
conventional medication. 
 
Estimates of the prevalence of TD in first onset cohorts are 6.3% in first year, 11.5% at two 
years, 13.7% at three years and 17.5% at four years. Overall, prevalence rates vary 
between 15% and 50% at two years.
33
 Risk factors for developing TD, apart from 
antipsychotic use, are dose of drug used, poor response to initial treatment, structural brain 
abnormalities, mental impairment, alcohol abuse and possibly diabetes. 
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TD was originally thought to be due to chronic dopamine blockade in particular D2 receptors. 
However, it is now seen to be much more complex than this. Interestingly, patients can 
develop TD without ever having taken antipsychotics, while some drugs that predominantly 
block D2  receptors, such as, sulpiride, still have very low rates of inducing TD.
34,35
 
 
Conventional antipsychotics block a broad spectrum of neurotransmitters and, although 
EPSE are common and troublesome, there are many more adverse effects.  
 
Table 6 Summary of Common Adverse Effects of Conventional Antipsychotics 
Side Effect 
 Extrapyramidal (including acute dystonia, parkinsonism, akathisia, tardive dysknesia) 
 Hypotension 
 Hypothermia 
 Neuroleptic malignant syndrome (fluctuating consciousness, autonomic dysfunction and 
rigidity) 
 Sedation 
 Cardiac dysrhythmias 
 Endocrine effects (galactorrhoea, gynaecomastia, impotence, weight gain) 
 Agranulocytosis, leucopenia, haemolytic anaemia 
 Photosensitisation 
 Anticholinergic (dry mouth, blurred vision, constipation, urinary retention) 
 Lowering of seizure threshold 
 
 
2.1.4  Summary of Evidence for Conventional Drug Therapy 
 
To summarise the position with relation to the clinical effectiveness of conventional 
antipsychotic drugs: 
 
 30-40% of patients do not respond during acute episode; 
 They are largely ineffective against the negative symptoms of schizophrenia; 
 They are largely ineffective at increasing social/vocational activities, despite alleviating 
symptoms; 
 They are associated with medication compliance problems; 
 Up to 40% of patients will relapse within two years despite prophylaxis; 
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 Up to 75% of patients will experience EPSE; 
 5% of patients per year will develop TD. 
  
2.2  ‘Atypicals’: The Theoretical Case 
 
The following sections consider in turn the existing body of trial evidence related to the 
clinical effectiveness of the ‘atypical’ antipsychotic drugs. 
 
Before beginning to discuss the evidence behind the development and use of newer 
‘atypical’ drug compounds, it is necessary to emphasise the two separate arguments for 
their use, which are commonly and erroneously amalgamated, those of treatment resistance 
and of the treatment of negative symptoms.  
  
1. Newer compounds have fewer adverse effects than conventional drugs and are probably 
effective against negative symptoms.  
  
2. Treatment resistance is not synonymous with continuing negative symptoms. To date, 
only clozapine has a licence for use in previously treatment-resistant patients. 
 
2.3  Clinical Evidence Base: Clozapine 
 
Clozapine is an antipsychotic drug licensed for use in treatment-resistant schizophrenic 
patients only (i.e. those patients who are deemed non-responsive to two or more 
conventional antipsychotics). The following presents the current view of strength of trial 
evidence for the clinical effectiveness of clozapine in this group of patients. 
 
The majority of the published (independent) literature related to antipsychotics in general is 
on the use of clozapine; this is because it has now been available for nearly 10 years. Much 
of the trial evidence, in the form of both controlled trials and larger open labelled studies, 
compares clozapine to conventional drugs, typically chlorpromazine or haloperidol. 
 
A 1993  Wessex DEC Report
36
 considered the use of clozapine in treatment resistant 
schizophrenia. As part of this report consideration was given to an important review of the 
effectiveness of clozapine conducted by Baldessarini et al.
37
 This study  considered 14 key 
controlled clinical trials and identified a range of response rates which varied across the 
trials from 7% to 33% above that of the conventional treatment arms. Baldessarini 
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calculated that, on average, clozapine patients would achieve a 13% improvement in 
response rate. Of the 14 trials identified, five were deemed to be conducted in well-defined 
groups of schizophrenic patients.  
 
These trials are summarised in the table below, along with two further trials, which also 
consider clozapine in treatment resistant patients. The table also cites additional longer-term 
and open studies of clozapine which, whilst not of a fully controlled and randomised design, 
do provide some useful information as to the longer-term potential benefits of treatment. 
 
2.3.1  Response Rate 
 
As stated, the 14 trials originally considered in the Baldessarini report provide a range of 
extra response of between 7-33%. The best and most respected of the considered trials 
from this study is the Kane study.
38
  In this classic study of 268 treatment resistant patients,  
30% responded to clozapine compared with only 4% of a chlorpromazine control group. 
Other studies have reported similar findings showing response rates to clozapine between 
30-50%.
39,40
 
 
Predicting patients who are likely to respond to clozapine is more difficult. In the Kane 
study,
38 
 those most likely to respond had more paranoid symptoms, less grandiosity and a 
higher number of admissions. 
 
It is important to distinguish between effectiveness in refractory cases and effectiveness in 
the treatment of negative symptoms. Clozapine is certainly superior in the former, the latter 
is more controversial. Negative symptoms occur either as primary symptoms, or arise as 
secondary phenomena associated with a number of factors, but more importantly 
conventional antipsychotic drug use. Thus, as patients are transferred onto clozapine from 
conventional drugs, the apparent decrease in negative symptoms may be a decrease in 
secondary symptoms only. Kane reports some, but slower, improvement in negative 
symptoms probably due to decreased use of older drugs. In a 1994 report Breier describes 
the effects of clozapine on negative symptoms as relatively minor and largely restricted to 
patients with a non-deficit state.
41
 European chlorpromazine/clozapine and 
haloperidol/clozapine trials  support this view reporting only partial response in a severely ill 
(i.e. prominent negative symptoms) cohort.
42 
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Table 7 Supporting RCTs for Clozapine 
Trial Design Summary of Key Findings 
Kane et al. 
1988
38
 
Two armed multi centred  
randomised study. 
Clozapine (<900mg)  vs 
Chlorpromazine (<1800mg) 
6 week trial. 
268 treatment resistant patients. 
(haloperidol 60mg/day). 
Clozapine had significantly fewer EPSE (p<0.05) 
Clozapine had a significantly greater overall 
efficacy (p<0.05) 
Clozapine had a 30% clinical response rate c.f. 
4% with chlorpromazine 
Claghorn et al. 
1987
43
 
Randomised double blind trial. 
Multi-centred. 
Parallel group. 
Clozapine (150-900mg) vs 
Chlorpromazine (300-1800mg). 
8 weeks. 
124 patients with TD / EPSE on 
conventional drugs. 
Clozapine had fewer EPSE 
Clozapine had a significant greater overall 
efficacy (p<0.05) 
Conley et al. 
1988
44
 
Randomised double blind trial. 
Parallel group. 
Clozapine (<900mg)  vs 
Chlorpromazine (<1800mg). 
6 weeks. 
24 treatment resistant patients 
(haloperidol 60mg/day)  
Clozapine had fewer EPSE  
Clozapine had a significant greater overall 
efficacy (p<0.05) 
Herrera et al. 
1988
45
 
Double blind trial. 
Parallel group. 
Clozapine (900mg)  vs 
Chlorpromazine (1800mg). 
6 weeks. 
60 treatment resistant patients 
(haloperidol 60mg/day). 
Similar EPSE noted 
Clozapine had a tendency towards a greater 
clinical effect 
Borison et al. 
1988
46
 
Randomised double blind trial. 
Comparison group. 
Clozapine(<900mg)  vs 
Chlorpromazine (<1800mg). 
6 weeks. 
27 treatment resistant patients. 
(haloperidol 60mg/day). 
 
 
No observation on EPSE 
Clozapine had a significant greater overall 
efficacy (p<0.05) 
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Trial Design Summary of Key Findings 
 
Breier et al. 
1994
41
 
 
 
Double blind study. 
10 week. 
Clozapine vs haloperidol. 
40 schizophrenic patients. 
 
 
Measures : BPRS, SANS 
Clozapine appeared superior in both negative 
and positive symptoms 
 
Pickar et al. 
1992
47
 
Double blind placebo control trial 
Clozapine vs fluphenazine or placebo 
21 treatment resistant patients 
Measures : BPRS, SANS 
Clozapine superior to both trial arms in total 
score, negative score and positive score 
Retrospective case studies 
UK Clozapine 
Study Group 
1994
48
 
Open study 
54 chronic patients 
No response to 3 conventional drugs 
6 month follow up 
77% patients achieved a 25% improvement 
42% patients achieved a 50% improvement 
Improvement defined at 8 weeks and maintained 
for 6 months  
Measures : BPRS/NOSIE/PSS/CGI/SARS/AIMS 
Revecki et al. 
1990
49
 
Retrospective case-controlled study 
of Clozapine 
133 patients on clozapine 
28% re-admission rate at 2 years c.f. 56% in 
conventional control group 
 
Honigford et al. 
1990
50
 
Retrospective case-controlled study 
of Clozapine 
86 patients on clozapine 
28% re-admission rate at 2 years c.f. 56% in 
conventional control group  
(NB: figures same as in Revecki study) 
 
 
2.3.2  Relapse Rate 
 
There is also good evidence that clozapine reduces rates of relapse and decreases the 
number of re-admissions.
39, 51,52
 
 
2.3.3  Side-effects and Contra-indications  
 
The most common side-effects of clozapine noted from the key trial evidence are: sedation; 
excessive salivation; weight gain and othostatic hypotension. However, the most serious 
potential side-effect of clozapine is the risk of agranulocytosis. 
 
Clozapine’s ability to cause agranulocytosis is well recognised and resulted in its initial 
withdrawal  in the 1970s. With the development of a comprehensive monitoring system, the 
hazards can be virtually eliminated. A  study of over 11,000 patients reported an incidence 
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of 0.8% after one year and 0.9% at 18 months.
53
  The incidence peaks at three months. This 
compares with an approximate incidence of agranulocytosis using phenothiazines of 1 in 
1,300, a probable under-estimate.
54
 The clozapine patient monitoring system (CPMS) 
initially requires baseline, weekly and eventually monthly white blood cell counts; medication 
is only provided if the counts are within a normal range. If the count falls, clozapine is 
stopped and the count will return to normal. This facility can currently only be provided by 
the manufacturer and dramatically increases the costs. However, to date there have only 
been two deaths reported due to agranulocytosis since the drug’s re-introduction. 
 
Clozapine also carries a risk of seizure which is noted in trials as dose related with incidence 
rate of 5-10% at dosage above 600mg/day. 
 
The following table summarises the side-effect profile of clozapine and is taken directly from 
the Wessex DEC report.
36
 The data are based on both published and unpublished trial 
results and on file data covering in total 15,000 patients. 
 
Table 8 Clozapine's Side-effects - Wessex DEC Report
36
 
Side Effect Incidence Rate  
Sedation  34% 
Weight Gain  34% 
Excessive Salivation  23% 
Gastrointestinal symptoms  17% 
Hypotension  11% 
Fever  5% 
Seizure  4% 
Agranulocytosis  1% 
 
2.3.4  Clinical Summary  
 
There is a wide range of clinical trial evidence now available related to the use of clozapine 
in treatment-resistant patients. Most studies imply a relative freedom from relapse and show 
better clinical response and lower re-admission rates against conventional treatment. 
 
The Wessex report considered the evidence of effectiveness and the potential benefits to 
patients and the NHS of clozapine and came to the overall conclusion of recommending its 
use in treatment-resistant patients. 
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There is a general clinical consensus and support for the use of clozapine in treatment-
refractory schizophrenia. It is now widely accepted that clozapine provides a better clinical 
response in treatment-resistant patients than conventional drugs. 
 
2.4  Clinical Evidence Base: Olanzapine 
 
Olanzapine is a thienobenzodiazepine, which has a high affinity for the D4, D1 and D2 
dopamine, muscarinic, alpha-1 adrenergic, 5HT2a, 5HT2c and histamine H1 receptors. 
 
It is similar to clozapine in chemical structure and in some neuroreceptor activities. However, 
it does not cause agranulocytosis, thus eliminating the need for weekly blood testing. 
 
With a half-life of between 24-35 hours, irrespective of hepatic and renal impairment, 
olanzapine can be administered in a single daily dose.
55
 The usual therapeutic dosage 
range is 5 to 20mg/day, with a recommended dose of 10mg/day. Olanzapine reaches peak 
plasma concentrations at about 5-8 hours after oral administration. 
 
In terms of evidence for efficacy, many of the existing trials relate to the short-term effects of 
olanzapine. The key randomised controlled trials (RCTs) on olanzapine are summarised in 
the following table. 
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Table 9 Supporting RCTs for Olanzapine 
Trial Design Summary of Key Findings 
Beasley, Tollefson 
et al. 1996
56
 
Olanzapine vs haloperidol 
Randomised double blind 
6 week trial 
335 patients 
More effective than placebo 
As effective as conventional drugs 
Olanzapine  (15mg/day) is more 
effective than haloperidol in the 
negative symptoms 
Beasley, Sanger et 
al. 1996
57
 
Olanzapine 1mg /10mg vs 
placebo 
6 week trial 
Randomised double blind 
trial 
152 patients 
Olanzapine (1mg/day)  equivalent 
efficacy to placebo 
EPSE not above placebo level 
Superior efficacy at 10mg in both 
positive (p<0.001) and negative 
symptoms  
Beasley, Hamilton 
et al. 1997
58
 
Olanzapine vs haloperidol 
6 week trial 
Double blind 
431 patients 
Olanzapine had equal overall efficacy to 
haloperidol 
Tollefsson et al. 
1997
59
 
Olanzapine(5/10/20mg)  vs 
haloperidol(5-20mg) 
1,996 patients 
6 weeks 
Lower levels of EPSE 
66% olanzapine patients completed the 
study c.f. 47% haloperidol patients 
(p<0.05) 
Similar efficacy in positive symptoms 
Statistically greater efficacy in negative 
symptoms 
 
To date, there have been four notable double blind randomised controlled clinical trials 
focused specifically on olanzapine. In total, approximately 3,000 patients were involved in 
the trials in direct comparisons with haloperidol or placebo as control arms. Dosages of 
olanzapine varied between 5-20mg/day, with the recommended dose set now at 10mg/day. 
 
Each of the trials lasted over a six week period, which is noticeably short when considering 
treatments for psychosis. Again, as is common in antipsychotic drug studies, these trials are 
primarily pharmaceutical company sponsored. However, they are generally considered to be 
of a high standard and well conducted. 
 
2.4.1  Response rate 
 
The first trial found olanzapine to be more effective than placebo and as effective as 
haloperidol in the control of the positive symptoms of schizophrenia.
56
 This observation was 
made using a measure of mean reduction in the BPRS from  original baseline observations. 
Using the SANS rating scale to focus on negative symptoms in particular, the study also 
revealed that olanzapine was more effective than placebo and haloperidol when applied at a 
dosage of 15mg. 
 
  29 
In the second trial, 152 schizophrenic patients were randomised to 1mg/day olanzapine, 
10mg/day olanzapine or placebo.
57
 The 1mg/day olanzapine was shown only to be 
equivalent to placebo in all efficacy comparisons. However, the 10mg dose olanzapine had 
statistically superior efficacy over placebo in both positive and negative symptoms of 
schizophrenia, when considered on both the BPRS and PANSS rating scales. EPSE levels 
were not noted above the placebo levels. Clinical response was defined as a 40% decrease 
in baseline BPRS scores or a final score 18. 
 
The third trial showed olanzapine to have equal efficacy to haloperidol in both the positive 
and negative symptoms.
58
 
 
The fourth trial compared 5-20mg/day doses of olanzapine to a range of doses of 
haloperidol 5-20mg/day and, again, was based over a six week period of time.
59
  The patient 
group included 1,996 schizophrenic, schizophreniform and schizoaffective patients. 
Interestingly, 65% of olanzapine treated patients completed the study compared to 47% in 
the conventional treated group. A similar efficacy in the positive symptoms was noted 
between olanzapine and haloperidol, with no statistically significant differences in 
effectiveness. Patients treated with olanzapine had statistically greater improvement in 
negative symptoms than their haloperidol counterparts. At study conclusion, olanzapine 
patients were reported to have an average decrease of 4.5 points on the PANSS negative 
symptom scale, compared to an average decrease of 3.2 points in patients treated with 
haloperidol. Patients treated with olanzapine showed comparable improvements to 
haloperidol patients in positive symptom improvement.  
 
Also, Olanzapine was associated with lower levels of EPSE with scores decreasing during 
treatment. The percentage of patients with treatment-emergent Parkinsonism was 
significantly lower (14% : 28%) in the olanzapine arm, as was the percentage of patients 
with an overall Barnes scale global score (12% : 40%). 
 
2.4.2  Relapse rate 
 
Much of the trial evidence for olanzapine is in acute phase studies. There is very little 
evidence available, as yet, about the long-term efficacy. The results of a one year follow-up 
study to the Tollefson trial shows rehospitalisation rates of 20% with olanzapine compared 
to 28% for the haloperidol group. 
 
2.4.3  Side-effects and Contra-indications 
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Common side-effects of olanzapine include somnolence, dizziness not related to 
hypotension, and weight gain. These are generally expected in around 10% of patients. 
 
Less prevalent side-effects include: increased appetite, peripheral oedema, constipation, dry 
mouth, and are observed in between 1-10% of patients. 
 
In a combination analysis of three clinical studies, patients receiving olanzapine were less 
likely to report treatment related EPSE symptoms. About 8.5% of olanzapine patients 
exhibited long-term treatment-emergent TD symptoms at any baseline visit, compared with 
17.3% of haloperidol patients. 
 
The most common side-effects associated with olanzapine reported were insomnia (10.4%), 
dry mouth (7.5%), akathisia or uncontrollable motor restlessness (6.6%) and nervousness 
(5.6%). There have been no reported cases of agranulocytosis. 
 
There have been significant contra-indications noted: 
 
 taking alcohol with olanzapine can increase heart rate and lead to dizziness; 
 contra-indications in pregnancy and in breast feeding women; 
 contra-indications in patients with a risk of narrow-angle glaucoma. 
 
2.4.4  Clinical Summary 
 
The four trials supporting olanzapine have been relatively well received in the published 
literature and demonstrate the clinical equivalence to haloperidol over the short term. 
However, as the trials were all based over six week periods, it is very difficult to be certain 
over a  longer time period.  
 
Therefore: 
 
 Olanzapine’s efficacy against the negative symptoms of schizophrenia seems superior to 
that of conventional drugs over the short-term; 
  
 Olanzapine should be considered to be equally effective in terms of positive aspects of 
schizophrenia over the short-term; 
  31 
  
 Olanzapine demonstrates similar EPSE levels as with placebo, these being significantly 
lower than those with conventional drug therapy; 
  
 Olanzapine appears to have a better compliance profile than conventional drugs; 
  
 Efficacy in treatment-resistant patients remains unproven with a need for further trial 
evidence in this specific group of patients. 
  
2.5  Clinical Evidence Base: Risperidone 
 
There is an established set of published clinical trials which relate to risperidone. Also, a 
Wessex DEC report, considering risperidone in treatment-resistant schizophrenia, has been 
published;
68
 and, in addition, there is a recent meta-analysis conducted by Song et al.
60
  
 
The following summarises the evidence for the clinical effectiveness of risperidone and 
refers to both these reports. 
 
Song Meta-Analysis 
 
A meta-analysis of RCTs of risperidone in the treatment of schizophrenia was recently 
published.
60
 This analysis took account of 11 double-blind trials, which were identified in a 
review of standard data sources (Medline, EMbase, BIDS and PSYCLIT). 
 
The most common comparison arms were based on haloperidol (2mg-20mg) and/or 
placebo. The data were apparently pooled using the approach covered by Whitehead.
61
 
Details of the individual trials are summarised in Appendix A.  
 
The majority of patients entered into these 11 trials were hospitalised in-patients who were 
suffering from chronic schizophrenia. The mean time since onset was around 15 years and 
the mean duration of the current period on admission was six months. 
 
In evaluating effectiveness, clinical improvement was defined as a 20% reduction from 
baseline (the initial scale value of each patient) in the PANSS total score or the BPRS total 
score. Using the total score includes clinical effects on both the positive and negative 
symptoms. This 20% level matched the limits used in the clinical trials. However, there is no 
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definitive statement as to the exact clinical relevance of this limit (i.e. how much difference in 
terms of treatment and/or quality of life this 20% reduction would represent). 
 
Three specific outcome measures were explored within the meta-analysis and a summary of 
the main findings are presented in the following table. 
 
Table 10 Findings of the Meta-Analysis 
Meta Analysis:  
Outcome Measure 
Odds ratio 
with 95% 
confidence 
intervals 
Control 
Group 
Risperidone 
Group 
Number Needed 
to Treat for One 
Event Difference 
Showing clinical 
improvement 
1.27  
(1.04-1.56) 
52% 57% 20 
Using anti-Parkinsonian 
medication 
0.51 
(0.41-0.63) 
38% 23%   7 
Drop-out before end of 
trial 
0.75 
(0.61-0.94) 
34% 29% 20  
 
 
Across all the trials overall clinical improvement and response rate were noted on average to 
be better with risperidone than with conventional therapy (57% compared to 52%); odds 
ratio 1.27 (1.04, 1.56). This measure includes both the positive and negative symptoms of 
the illness.  
 
When considering further the individual negative symptoms of schizophrenia, there are eight 
trials which have specifically used the PANSS negative scores. These trials suggested that 
risperidone is more clinically effective than the control arm, with a pooled difference in the 
PANSS score between the risperidone and haloperidol groups of -0.74 (95% CI -1.50, 0.02), 
which has only borderline significance (p<0.058). 
 
The overall drop-out rate was also reported to be statistically significant between the two 
arms, with risperidone patients having a 29.1% rate compared to 33.9% with the control 
arm; odds ratio 0.75 ( 0.61, 0.94). 
 
Song discussed some of the differences found in the overall treatment effects between the 
trials. It was noted that one trial had a baseline PANSS score of 120.5, much higher than 
the other trials representing a chronic patient group, and two trials had relatively low PANSS 
and BPRS scores.
62,63,64
 There were also trials which had relatively low levels of risperidone 
dosages (1-2mg/day), which was felt to favour the conventional arm. In order partly to allow 
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for these potential differences, a number of alternative sensitivity analyses were presented, 
which excluded those trials with either low dosage levels or very different entry baseline 
rating scales. 
 
The results of the sensitivity analysis do not alter the overall outcomes of the meta-analysis 
when compared with an all trial based analysis. Only scenario 2 removes any of the 
statistical significance, however this scenario includes all sub- and supra-therapeutic 
dosages of risperidone. 
 
Table 11 Risperidone Meta-Analysis Sensitivity Analysis 
 Odds ratio with 95% Confidence Interval 
 Clinical 
Improvement 
Drop-Out Rate Use of EPSE 
medication 
All Trials 1.27 (1.04, 1.56) 0.75 (0.61, 0.94) 0.51 (0.41, 0.63) 
Scenario 1 1.34 (1.09, 1.64) 0.73 (0.58, 0.91) 0.57 (0.46, 0.70) 
Scenario 2 1.20 (0.96, 1.49) 0.81 (0.63, 1.03) 0.55 (0.44, 0.71) 
Scenario 3 1.33 (1.05, 1.68) 0.75 (0.57, 0.97) 0.54 (0.42, 0.70) 
  
 
 
Scenario 1:  Excludes sub-therapeutic risperidone dosage <4mg/day (Chouinard et al.
65
, Marder 
et al.
66
 and Peuskens et al.
67
) 
Scenario 2:  Excludes Chouinard et al., Marder et al. 
Scenario 3: Excludes Chouinard et al., Marder et al., all sub-therapeutic risperidone dosages 
<4mg.day and supra-therapeutic dosages >10mg/day (Peuskens et al.) 
 
 
Wessex DEC Report 
 
The Wessex DEC Report No 48
68
 recently considered the use of risperidone in treatment 
refractory schizophrenia. Risperidone was compared to clozapine, already used in 
treatment-resistant patients. The report reflected on the fact that there are no suitable trials 
of risperidone in truly treatment-resistant patients and, only one trial exists, which places it in 
a direct ‘head to head’ comparison with clozapine.
69
 This trial showed an equivalent efficacy 
but, importantly, was based on a relatively small sample size of 59 patients and, as with the 
other trial evidence, was very much based on a short-term time span of four weeks. The 
patients included were not all of a truly refractory nature. 
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The Wessex report concludes that the case for risperidone in refractory schizophrenia 
remains unproven. A summary of the trial evidence used can be found in Appendix A. 
 
2.5.1  Side-effects and Contra-indications 
 
From the meta-analysis of trials, a combination of pooled results indicated that the use of 
related medication related to EPSE was 23% in the risperidone group and 38.4% in the 
conventional haloperidol group. 
 
Also, when combining the trial results, 18.7% of risperidone patients reported EPSE  
compared to 35.1% in the conventional drug patients. When compared to the levels of 
EPSE reported from the olanzapine trials, it was noted that there were large differences. 
The combined study of olanzapine reported 17.3% rates for haloperidol patients. Clearly, it 
is very difficult to draw any suitable comparisons of ‘atypicals’ without direct trials. 
 
Risperidone was shown to be associated with significantly (p<0.05) more cases of weight 
gain and tachycardia above the rate observed for conventional antipsychotics. 
 
Other noted side-effects include insomnia, anxiety, agitation and sedation. 
 
2.5.2  Clinical Summary 
 
The meta-analysis concludes that the short-term efficacy of risperidone is comparable to 
conventional antipsychotics. It can also be seen to be associated with a lower rate of EPSE, 
a common side-effect of conventional drugs. 
 
There is still a need for more longer-term studies of risperidone. 
 
 Risperidone presents less EPSE than those associated with conventional antipsychotics, 
although low levels of EPSE are reported at dose 10mg/day. 
  
 Risperidone appears to be more effective in respect of the negative symptoms, but this 
was based on a result of borderline statistical significance and has only been 
demonstrated over the short-term. 
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 Risperidone is observed to have an overall equivalent efficacy to conventional drugs 
when considering total rating scores in acute trials. 
 
Risperidone mimics clozapine to some extent in showing reduced motor side-effects even 
though predominantly in low dose ranges, and the drug lacks most of the serious side-
effects of clozapine, like agranulocytosis, cardiac effects, and seizure induction.  
 
In terms of treatment-refractory patients, the efficacy of risperisone has not yet been 
demonstrated, however studies are currently underway in comparison with clozapine. 
 
2.6  Clinical Evidence Base: Sertindole 
 
Sertindole is an ‘atypical’ antipsychotic, manufactured by Lundbeck as Serdolect, which is 
said to have a selective inhibitory effect on mesolimbic dopaminergic neurones.  
 
Sertindole is demonstrated to be a potent antagonist at dopamine D2, 5HT2, and alpha1-
receptors without activity at histaminic H1 or muscarinic receptors. This selectivity should 
not produce sedative effects or anticholinergic effects related to other receptors. 
 
There are still only two published trials which have focused on the use of sertindole in the 
treatment of schizophrenia, these are listed in the table below. 
 
The Van Kammen trial was a dose ranging study, which was controlled and lasted over a 
period of 40 days. The study involved 205 in-patients with a previous clinical response to 
antipsychotics. The study explored three dosages of sertindole (8,12 and 20mg/day) against 
a placebo control arm.
70
 
 
The study found that only the 20mg dose of sertindole showed an increased effectiveness 
over placebo in both positive and negative symptoms, using the CGI as an outcome 
measurement scale.  
 
In terms of side-effects, the incidence of EPSE was found to be no different irrespective of 
dosage or control arm.  
 
The Zimbroff study was a multi-centre, double-blind, eight-week clinical trial which was  
designed to compare three doses of sertindole (12, 20 and 24mg/day) with three doses of 
haloperidol (4, 8 and 16mg/day) and also a placebo control arm. Within the study, all 
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sertindole doses and haloperidol doses showed significant improvement in the positive 
symptoms of schizophrenia compared with placebo and in reducing the total scores on the 
PANSS.
71
 
 
Table 12 Supporting RCTs for Sertindole 
Trial Design Summary of Key Findings 
Van Kammen et al. (1996)
70
 Randomised, double blind 
dose ranging study. 
Sertindole 
(1mg/12mg/20mg) vs 
placebo. 
205 schizophrenic patients.  
40 day trial. 
At 20mg sertindole has 
significantly greater efficacy 
on both positive and 
negative symptoms. 
105 patients completed 
study. 
 
Zimbroff, Kane et al. (1997)
71
 Multi-trial, seven centre, 
dose ranging double blind 
trial. 
497 patients - 20 excluded 
from intention to treat. 
8 week study . 
Sertindole  has significantly 
greater efficacy over placebo 
in PANSS  total score 
(p<0.05). 
At 20mg sertindole also 
reduced negative symptoms 
as per PANSS  and SANS. 
No difference in reported 
EPSE levels. 
 
 
Only sertindole, at a dose of 20mg/day, was noted as reducing the negative symptoms of 
schizophrenia, as measured by the PANSS Negative Symptom Sub-scale and total SANS 
(p<0.001).  
 
On a comprehensive global scale of improvement (the CGI), all doses of sertindole and 
haloperidol were associated with significant improvement compared to placebo.  
 
Within the study, EPSE rates were measured by the number of EPSE-related adverse 
events, use of anti-EPSE medication and three standardised movement rating scales. 
Patients using haloperidol experienced rates significantly higher than in the placebo arm, 
confirming the known relationship between conventional drugs. EPSE-profiles for sertindole 
were clinically and statistically indistinguishable from placebo. In addition, patients treated 
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with sertindole, irrespective of dose, exhibited significantly less EPSE than patients using 
haloperidol.  
 
The adverse events that occurred more often with sertindole than placebo included nasal 
congestion and decreased ejaculatory volume. The adverse events that occurred more often 
with haloperidol than placebo were EPSE-related. 
 
2.6.1  Side-effects and Contra-indications 
 
In clinical trials, the most commonly noted side-effects with sertindole compared to placebo 
arms are prolongation of the QTc interval, reduced ejaculatory volume and nasal 
congestion. Also, there are a series of lesser problems associated with: weight gain; dry 
mouth; dizziness; postural hypotension; headache; and insomnia. 
 
The non-sedating nature of sertindole has also been noted and is an important 
consideration when selecting appropriate patients for sertindole-based therapy. 
  
The contra-indications for sertindole include: 
 cardiovascular disease; 
 pregnancy; 
 breast-feeding; 
 history of seizures. 
 
Care is required in respect of use in: 
 diabetes (adjustment to antidiabetic therapy may be needed); 
 patients with hepatic impairment (may require lower dosage and slower titrations); 
 patients on fluoxetine or paroxetine (may require a dosage reduction due to low 
metabolism rates for sertindole). 
 
The information on contra-indications and treatment considerations is well published and 
can be found in more detail in the Drug and Therapeutics Bulletin
72
 and the Trent Drugs 
Information Service Monograph: Sertindole.
73
  
 
2.6.2  Cardiac Conduction Changes 
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Sertindole can cause a prolongation of the QTc interval as measured by an ECG. This 
electrical conduction defect can potentially cause cardiac dysrhythmias, including torsade 
des pointes. The incidence of this adverse effect is approximated at 1.7% of patients taking 
sertindole.
74
 The effect is most commonly observed within the first 3-6 weeks of treatment 
and appears not to be dose related. Since its introduction, the manufactures of sertindole 
have altered the prescribing and monitoring guidelines and now recommend a baseline ECG 
and regular ECG monitoring during dose titration and during continuing treatment. If ECG 
changes reach a pre-defined level, then it is advised that the drug treatment is stopped. This 
requirement for monitoring presents an obvious extra element of cost in using sertindole. 
 
Some uncertainty remains over the implications of this finding. Comparative trials will 
probably reveal no difference in QTc between sertindole and conventional antipsychotic 
drugs. To date, there have been no reports of life-threatening arrhythmias in patients on 
sertindole.
75
 
 
2.6.3  Clinical Summary 
 
In summary, the two trials provide a valuable insight into the dosage effects. However, it 
must be said that the length of time covered by both is relatively short and it is impossible to 
draw any firm longer-term conclusions from their results. 
 
In comparative terms, sertindole does present a range of contra-indications and treatment 
interactions, in particular, the issues around QTc interval, which are commonly seen by 
clinicians as a barrier to their use and acceptance by patients. This is especially the case as 
there are no proven efficacy benefits over any of the other ‘atypical’ drugs. It has also been 
noted that, in comparative terms, the marketing push for sertindole has been noticeably less 
than for its competitors.  
 
Taking all points into consideration, the evidence for effectiveness of sertindole appears 
credible over the short-term but remains to be proven in a longer-term setting.  
 
Post DEC Meeting Note: On December 3, 1998 sertindole was withdrawn by Lundbeck 
due to established cardiac toxicity problems (which have been discussed above). 
 
2.7  Summary of ‘Atypical’ Antipsychotics 
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The following brings together a summary of the current clinical views on ‘atypical’ 
antipsychotics. 
 
2.7.1  Side-effects 
 
The real potential benefit of ‘atypical’ antipsychotics is seen as their reduced levels of side-
effects when compared to the existing conventional drug treatments. Most of the reported 
trials compare ‘atypical’ antipsychotics with conventional and placebo control arms and 
make direct comparisons of side-effects, with a particular focus on the EPSE group of more 
serious neurological adverse effects. 
 
The following table presents and summarises the typical range of side-effects, noted from 
trial evidence, for the main ‘atypical’ drugs. 
 
Table 13 Summary of Side-effect Profiles of Newer Antipsychotics 
Clozapine   sedation 
 seizures 
 hypo-hypertension 
 hypersalivation 
 weight gain 
 constipation 
 agranulocytosis 
Sertindole  nasal congestion 
 decreased ejaculatory 
volume 
 dizziness 
 dry mouth 
 orthostatic hypotension 
 weight gain 
 prolonged QTc interval 
Risperidone  insomnia 
 agitation 
 anxiety 
 headache 
 somnolence 
 hypotension 
 EPSE (dose >10 mg) 
Olanzapine  somnolence 
 weight gain 
 dizziness 
 peripheral oedema 
 orthostatic hypotension 
 constipation 
 dry mouth 
 
Noticeably, only risperidone has shown any notable levels of EPSE, which was very much 
related to the higher dosage use of the drug. Even these levels were lower than in 
conventional therapy. 
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The occurrence of EPSE is extremely low in patients on clozapine and it may actually help 
improve TD.
38,32
 Lieberman et al. report a 50% decrease in TD symptom severity in 40% of 
patients taking clozapine.
76
  Similar findings are reported for the other new compounds.  
 
Sertindole causes significantly less EPSE compared with haloperidol (18% vs 47%), overall 
the same rate as in a placebo-controlled group. There are limited data on its long-term use, 
but early reports suggest lower rates of TD (2% c.f. 8% at 1 year). Olanzapine produced 
near identical findings with rates of EPSE no different from placebo-controlled groups.  
 
Studies on risperidone are less clear cut, at lower doses (6-8mgs) rates of EPSE are 
minimal, but these side-effects become more apparent with higher doses of 12-16mgs a 
day. 
 
A study report, published by Casey, considered the side-effect profiles of ‘atypicals’ and 
conventional drugs.
77
 
 
The report based its findings on a summary covering a number of disparate trial results. 
Whilst this has problems in terms of the obvious differences in clinical settings and 
assessment schedules, it does provide a valuable insight into the side-effect benefits and 
their potential to influence compliance.  
 
The report draws out and highlights three key side-effects related to ‘atypicals’: 
 
 EPSE associated with high doses of risperidone; 
 agranulocytosis as a potential adverse effect of clozapine; 
 the QTc interval lengthening associated with sertindole. 
 
More generally, the report draws attention to the tendency for patients to increase weight 
with all the ‘atypical’ drugs and the general low level of sedation in the newer ‘atypicals’ 
(excluding clozapine), especially in the case of sertindole. 
 
The study finally calls for more structured and controlled ‘head-to-head’ comparisons of 
drugs. 
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Table 14 Comparative Side-effects of the New Antipsychotic Agents 
Item Typical 
Neuroleptics 
Clozapine Risperidone Olanzapine Sertindole 
CNS Extrapyramidal side-
effects 
+ to +++ 0 0 to ++
ab
 0
a
 0
a
 
Tardive dyskinesia (TD) +++ 0 ? ? ? 
Seizures 0 to + +++ 0 0 0 
Sedation + to +++ +++ + + 0 
Neuroleptic malignant 
syndrome (NMS) 
+ + + ? ? 
Orthostatic hypotension + to +++ 0 to +++ + + + 
QTc 0 to +++ 0 0 to + 0 ++ 
Liver transaminase increase 0 to ++ 0 to + 0 to + 0 to + 0 
Anticholinergic + to +++ +++ 0 + 0 
Agranulocytosis 0 +++ 0 0 0 
Prolactin increase ++ to +++ 0 0 to ++ 0
c
 0c 
Decreased ejaculatory 
volume 
0 to + 0 0 0 ++ 
Weight gain 0 to ++ +++ ++ ++ ++ 
Nasal congestion 0 to + 0 to + 0 to + 0 to + ++ 
 
Symbols:  
0 =  none or not significantly different from placebo: 
+ =  mild 
++ = moderate 
+++ = marked 
? =  insufficient data available 
a
 =  Not significantly different from placebo-treated group, which may have received typical neuroleptics 
before entering the study and could have EPSE carry forward into the initial weeks of the investigation. 
b
 =  Dose-related EPSE above 6mg/day. 
c
 =  Dose related increases within the normal range. 
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The following table provides a helpful summary of the potential side-effects behind ‘atypical’ 
antipsychotics. 
 
Table 15 Adverse Effects of ‘Atypical’ Drugs Compared with Haloperidol 
Drug Acute EPSE TD NMS Hypotension Hyper-
prolactinaemia 
Haloperidol +++ +++ +++ + +++ 
Clozapine - - - +++ - 
Risperidone + ? ++ ++ +++ 
Sertindole - ? ? - - 
Olanzapine - ? ? - + 
 
2.7.2  Clinical Efficacy  
 
Risperidone, sertindole, olanzapine and quetiapine have been shown to be at least equally 
effective as conventional antipsychotics in alleviating acute, or positive, symptoms of 
schizophrenia. There is evidence that they are all significantly better at improving negative 
symptoms, though again this may in part be due to secondary negative symptoms. 
 
An area which would produce short-term major cost reductions would be prevention of 
relapse and subsequent decrease in the number of days in hospital. There is evidence from 
retrospective studies and mirror-group studies which begin to point towards these kinds of 
benefits; thus, a significant reduction in hospital days for those patients on risperidone 
compared with conventional treatments has been reported.
87
 In a comparison of sertindol 
with haloperidol over a 12 month period, the mean number of days in hospital was 4.3 and 
18.4 respectively.
52
 There was also a decreased number of admissions in the sertindole 
group. Significant reductions in relapse rate for patients on olanzapine compared with 
haloperidol, 20% at one year compared with nearly 30% respectively has been reported.
57,58
 
There is a need for further longer-term studies on the use of ‘atypical’ antipsychotics. 
 
The following table provides a helpful summary of the strength of evidence behind ‘atypical’ 
antipsychotics. 
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Table 16 Efficacy of ‘Atypical’ Drugs Compared with Haloperidol 
Drug Positive symptoms Negative symptoms Refractory illness 
Haloperidol ++ + - 
Clozapine +++ +++ +++ 
Risperidone ++ ++ ? 
Sertindole ++ ++ ? 
Olanzapine ++ +++ ? 
 
 
In terms of efficacy in treatment-resistant patients, the ‘atypical’ compounds, other than 
clozapine, have not as yet been shown to be any better than conventional drugs in the 30% 
of patients who do not respond. Therefore, any statement about the use of ‘atypicals’ in true 
treatment-resistant patients is not based on hard clinical evidence. However, this may be 
about to change as trials are nearing completion - in particular, for olanzapine. 
 
2.7.3  Comparative or ’Head to Head’ Trials 
 
Unfortunately, the ‘atypicals’ have yet to be compared adequately with each other in direct 
clinical trials, most studies either compare with placebo or haloperidol. In comparison trials 
of ‘atypical’ drugs, there is currently very little published evidence available. There is an 
obvious need for a lot more direct comparative data to be made available. However, it is 
difficult to see how this is going to come from truly independent sources. 
 
One trial has been identified as part of the literature search. The trial is pharmaceutical 
company sponsored and has received much published comment in terms of the selection of 
dosages and comparator arms.
78
 
 
The Tran study was a double blind controlled trial of olanzapine versus risperidone in the 
treatment of schizophrenia. The trial took place in centres over nine countries and involved 
41 investigators. The severity of the patients' psychotic disorders at their entry into the study 
was quantified as a minimum BPRS score of 24 (BPRS extracted from the PANSS, items 0 
to 6). Patients were randomly assigned to receive either olanzapine or risperidone in a 1:1 
ratio for eight weeks of acute therapy and 20 weeks of continuing maintenance.  
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Table 17 ‘Head to Head’ ‘Atypical’ Drug Trials 
Trial Design Summary of Key Findings 
Tran et al.  1997
78
 Randomised double blind parallel 
study.  
Olanzapine (5-20mg/day) vs 
Risperidone (4-12 mg/day). 
8 week acute / 20 week 
maintenance. 
297 patients randomised. 
Similar drop out with olanzapine as 
in risperidone-treated patients. 
Comparable in overall efficacy. 
Better completion rate for 
olanzapine over 28 weeks. 
Olanzapine demonstrated lower 
relapse rates at 28 weeks (4% vs 
9%).  
 
Two hundred and twenty six patients completed the eight-week acute phase, with no 
statistically significant differences between the treatment groups in completion/drop-out 
rates. 
 
Olanzapine best met the investigators' first criteria for atypicality by having fewer EPSE  
than risperidone (monitored using the Simpson-Angus Scale (SAS) and in the frequency of 
use of anti-EPSE medications).  
 
In terms of anti-EPSE medication, a smaller proportion of olanzapine patients (17.9% vs 
31.5%) requested one or more doses of anticholinergic medication. In addition, statistically 
fewer olanzapine-treated patients experienced elevated prolactin levels after both eight 
weeks and 28 weeks than did those receiving risperidone.  
 
In efficacy measures, olanzapine and risperidone were comparable in reducing overall 
positive and negative symptoms of schizophrenia, although olanzapine achieved numerically 
superior mean changes on six of eight measures, and statistically significant superiority to 
risperidone in the PANSS mood sub-score at both eight and 28 weeks. In addition, at 28 
weeks, a statistically significant advantage with olanzapine was evident among patients who 
had achieved at least a 30% improvement on the PANSS total score.  
 
Fewer patients receiving olanzapine experienced relapse (4% at three months and 9% at six 
months) than did those treated with risperidone (9% at three months and 29% at six 
months). Relapse, a key measure of maintenance efficacy, was defined as a 20% or greater 
worsening in PANSS total score along with a Clinical Global Impression-Severity of Illness 
(CGI-S) score equal to or greater than three. 
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Tran concluded from this 28-week trial that olanzapine showed the key criteria for ‘atypical’ 
antipsychotic effects more often and to a greater degree than risperidone. Olanzapine was 
associated with fewer side-effects, less elevation of prolactin and greater efficacy in mood 
symptoms. At the dosages employed, he concluded that olanzapine was statistically 
significantly more likely than risperidone to evoke greater initial therapeutic response and 
less likely to be associated with relapse during maintenance therapy. 
 
2.7.4  Summary of Key Evidence  
 
 ‘Atypicals’ are generally better tolerated than conventional drug therapy; 
 ‘Atypicals’ have a lower observed rate of EPSE; 
 ‘Atypicals’ are at least as clinically effective as conventional drug therapy;  
 ‘Atypicals’ have the potential to influence negative symptoms; 
 Clozapine is currently the only drug shown to be effective in refractory schizophrenia; 
 ‘Atypicals’ represent a significant increase in pure drug costs; 
 ‘Atypicals’ have been shown to reduce longer-term relapse rates and hospitalisation in 
non-randomised studies. 
 
It must be re-iterated that these conclusions are based on short-term acute trials only. A 
summary of other ‘atypical’ antipsychotics is provided in the appendices. 
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3.  COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
The following section considers the overall cost implications of newer antipsychotics and 
their potential benefits. 
 
3.1  Cost Implications of ‘Atypical’ Antipsychotics 
 
3.1.1  Drug Costs 
 
The newer antipsychotic drugs are substantially more expensive than the older compounds, 
which is one of the reasons that their current levels of prescription are limited. The table 
below compares one year costs at 1996 prices for approximately equivalent doses. 
 
Table 18 Hospital Cost (£) for One Year Treatment, 1996 Prices.  
(Doses are approximately Equivalent) 
Drug Dosage Cost  
Chlorpromazine 
Haloperidol 
Sulpiride 
Trifluoperazine 
 600mg/day 
 20mg/day 
 1200mg/day 
 30mg/day 
 £33 
 £117 
 £75 
 £38 
Haloperidol Decanoate 
Zuclopenthixol Decanoate 
 100mg/2 weeks 
 200mg/2 weeks 
 £79 
 £85 
Clozapine 
Risperidone 
Sertindole 
Olanzapine 
 450mg/day 
 6mg/day 
 12-20mg/day 
 5-20mg/day 
 £3,094 
 £1,500 
 £1,337 
 £687-2,750 
 
Source : BNF March 1997 
 
It can be seen clearly that the cost of newer antipsychotics represents a significant increase 
over conventional drug therapy. The cost of clozapine remains high due to the requirement 
for regular blood testing, which is conducted centrally and funded through the drug pricing 
level. 
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3.1.2 Cost Burden on a ‘Typical’ District 
 
Using national epidemiological data and published prevalence rates (4 per 1,000 population 
‘at risk’) it can be predicted that an average district should realistically expect to have around 
1,300 schizophrenic patients living within the community. This represents all patients and, 
importantly, includes those not actually known to the existing healthcare services. 
  
Annually, a ‘typical’ district should expect an incidence of around 64 people experiencing 
first episodes of schizophrenia per annum. 
 
Recent patient audits in Nottingham reveal that there are approximately 30 new patients, 
within the Trust’s catchment area, with newly diagnosed pure schizophrenia every year 
(Brewin et al., 1997
4
) and this figure is reasonably steady. This value rises to around 168 
when including a broader definition of schizophrenia.  
 
Recent attempts to audit the level at which schizophrenic patients actually access services 
within the Nottingham area estimate the prevalence at somewhere between 1,200-1,300 
patients. Although the numbers in this patient group are difficult to assess, the totals 
identified fit reasonably well with the national prevalence estimates. 
 
If the generally accepted view is believed that 30% of new schizophrenics will respond well, 
with good prognosis, on conventional drugs, then it can reasonably be expected that the 
remaining 70% of the new patients will be suitable for ‘atypical’ antipsychotic drug therapy. 
Also, using haloperidol as a representative conventional drug, the marginal drug cost for 
these patients can be estimated at around £2,000. This cost represents the extra cost per 
patient spent above the cost of conventional treatment. Combining these estimates, it is 
seen that, for a ‘typical’ district, 45 new schizophrenic patients per annum (70% of 64 
patients) will be suitable for treatment on ‘atypical’ antipsychotics at an overall marginal cost 
of £90,000.  
 
If the lower Nottingham estimate of 20 suitable patients per year were to be accepted, then 
this value reduces to about £40,000.  
 
However, account must also be taken of the patients already known to the service, i.e. 1,300 
patients using the national figures. If the same 30%/70% split is applied to the patient 
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prevalence, 910 patients are identified who would not be expected to respond well to 
conventional drugs. 
 
Interestingly, the recent Nottingham Trust audit of proposed antipsychotic prescribing  
estimated that there were approximately 250 patients, out of a total of 1,200 -1,300, in need 
of these newer drugs, either because of intolerable side-effects or treatment resistance. 
This equates to roughly 20% of the current case-load. This lower level of suitable patients 
may be a direct reflection of the current restrictions in prescribing ‘atypicals’ rather than any 
real measure of need, but this remains unclear. 
 
The following presents the expected marginal cost for varying proportions of the current 
case-load being suitable for ‘atypical’ drugs. 
 
Table 19 Extra Direct Costs for a ‘Typical’ District due to ‘Atypical’ Drug 
Prescribing 
Proportion of 
Caseload 
Suitable for 
‘Atypical’ Drugs 
Number of 
Patients Suitable 
for ‘Atypical’ 
Drugs 
Marginal Cost 
per Patient  
Total Marginal 
Cost  
20% 260 £2,000    £520,000 
30% 390 £2,000    £780,000 
40% 520 £2,000 £1,040,000 
50% 650 £2,000 £1,300,000 
60% 780 £2,000 £1,560,000 
70% 910 £2,000 £1,820,000 
  
The total revenue for the Nottingham Healthcare NHS Trust in 1996/97 was £51 million. 
Approximately £752,000 or 1.6% of the total was spent on drugs. Antipsychotics accounted 
for only £225,000 and, within this figure, only 48 patients received the newer drugs, at a cost 
of £120,000; which emphasises the additional financial burden of the newer drugs. 
 
3.2  Potential Benefits of Antipsychotics 
 
The overall benefits of prescribing ‘atypical’ antipsychotic medication to schizophrenic 
patients are difficult to quantify in terms of  direct health service costs.  
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There appears to be a potential for a significant reduction in the level of serious side-effects 
for patients receiving these drugs. There may be very substantial benefits in terms of the 
natural history of the disease of a few patients, but the current evidence is unclear on this 
matter. Better compliance, partially due to improved tolerance, may also reduce relapse and 
re-admission rates and may have knock-on cost saving effects.  
 
However, some evidence suggests that patients receiving this medication may be more able 
to utilise existing rehabilitation services and, hence, have a cost increasing effect.  
 
Finally, these drugs  may have the effect of improving  quality of life, and that of families and  
carers but, as yet, these effects on quality of life are very difficult to quantify.    
 
3.3  Existing Cost-effectiveness Studies 
 
In terms of published studies which focus on the relative cost-effectiveness of newer 
antipsychotics, there is very little evidence currently available.  
 
One study, currently in press and funded by Eli Lilly,
79
 has considered the use of olanzapine 
in non-treatment resistant patients who have experienced multiple episodes. This study is 
based on a decision-tree model of patient pathways simulating the symptom characteristics 
of patients and repeatedly considering a three-monthly cycle of treatment over a five year 
time span. The study uses a decision tree structure based on a previous approach
49
  and 
has populated the model using data from literature, olanzapine trial data and UK clinical 
opinion. Results are expected to present a positive cost argument for olanzapine over 
haloperidol and, also, an advantage in clinical effectiveness, when considering the time 
spent by patients below a BPRS threshold of 18, which indicates a relatively good mental 
state. The authors are very clear in their description of the model as a theroretical estimate, 
listing out the range of assumptions necessarily taken. They also highlight the fact that 
health resource use data are extremely difficult to identify in mental health cases. The 
described process of expert panel and wide literature review highlights the levels of 
research resource required to conduct modelling exercises of this nature and stresses the 
need for clinical involvement.  
 
All remaining economic studies are centred on clozapine and its use in treatment resistant 
schizophrenic patients. 
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A recent editorial in the British Journal of Psychiatry helps to reiterate the overall view of the 
cost-effectiveness evidence with relation to drug treatments in schizophrenia.
80
 In 
commenting on a recent open small-sample study, it notes the real lack of large scale fully 
randomised and blinded study data in relation to schizophrenia and mental health generally. 
It also stresses the need for more longer-term studies, as much of the existing evidence is 
focused on the more immediate impact of drugs and their side-effects. This need for better 
and clearer evidence is stressed even more with the obvious cost implications of the 
‘atypical’ drugs. The article essentially continues the open debate regarding the relative 
ethics of short naturalistic studies and the longer-term prolonged randomised studies in 
mental health issues.  
 
Aitchison et al.
81
 recently considered the cost-effectiveness of clozapine in a UK based 
study comparing the three year history of patients not treated with clozapine to a following 
period of clozapine treatment.
 
The study involved 26 patients who had either chronic 
schizophrenia or schizoaffective disorder. The study claimed that the mean cost per annum 
of the patients on clozapine was £32,836 compared to £36,604 pre-clozapine, representing 
an annual net saving of £3,768. In terms of patient values, this represents a saving of £145 
per annum on an original patient cost of £1,407, an overall decrease of 10%. These costs 
included: hospitalisation/accommodation, drug cost and service use. The study also showed 
a lower level of unemployment following the introduction of clozapine (12 patients compared 
to 21). The study identified a reduced level of hospitalisation costs per patient with £19,740 
(60.1% of total mean cost post-clozapine) compared to £29,072 (79.4% under conventional 
treatment). 
 
Revicki et al.
49 
published a study of cost-effectiveness using clozapine in treatment-resistant 
patients compared to standard antipsychotic medication. The study was based on a 
retrospective comparison of two patient groups taken from seven centres in the USA. The 
cost study considered only the direct costs associated with the treatment and did not expand 
into the consideration of wider society costs, such as, unemployment, carer effects etc. The 
study was based on patients who were treatment-resistant to conventional drugs. The study 
claims that, although more costly in the first year, clozapine would be cost beneficial by the 
end of year 2 with a net saving of $12,622 (£8,000) when comparing a clozapine treated 
group to a non-clozapine comparator arm.  
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Questions were raised with regard to this study, in particular about the possibility of non-
resistant patients being included in the control arm and the exclusion of some hospitalisation 
costs. Overall, the study, even in a later re-worked form, remained inconclusive.  
 
Davies and Drummond
17
 published a study which considered further the cost-effectiveness 
of clozapine in treatment refractory schizophrenia. The basis of the paper was an economic 
model based on a decision tree developed from the Revicki retrospective cohort study. The 
study was not randomised and potential for bias remained. The underlying model was 
adapted to the UK in terms of cost and treatment management via the use of standard 
costings and clinical Delphi consensus exercises. The outcomes of the study suggested that 
clozapine remained cost-neutral and that, under the central estimates used, it actually 
reduced direct costs. A £91 per annum saving (£1,333 per lifetime) is forecast under the 
base case analysis. Also, a net gain of 5.87 years with mild disability is predicted as a 
benefit per patient lifetime. The paper concludes that prospective economic studies are 
necessary to confirm the results.  
 
Meltzer et al.
82
 published a further study of cost-effectiveness of clozapine in treatment-
resistant patients. This study was based on a cohort of 96 treatment-resistant patients with a 
two year history of schizophrenia prior to study. The study noted that the cost of treatment 
was significantly reduced if patients continued clozapine treatment for > 2 years. These cost 
savings were primarily due to the reduction in levels of hospitalisation. 
 
Chouinard et al.
83
 produced a utility analysis on the cost-effectiveness of risperidone. The 
basis for the analysis was the results of a multi-centred RCT by the same author, which 
compared risperidone with oral haloperidol. The original study was dose ranging and 
showed that risperidone at 6-16mg/day was superior to 20mg/day haloperidol on several of 
the symptom measures in PANNS. This study is different from the other published economic 
analyses of ‘atypicals’ as it does not claim a net cost reduction due to the drug, but does 
predict that a real benefit is achievable for the patient. The analysis uses the concept of 
Quality Adjusted Life Years (QALYs) to measure patient benefit. The utilities were calculated 
using the linear analogue and standard gamble techniques on patient profiles with ratings 
made by psychiatric nurses and not patients. The study reported an annual gain to patients 
of 0.075 QALYs per annum compared to conventional treatment. By comparing an 
incremental cost of £690 (Can $1600) to a gain of 0.075 QALYs, the estimated cost per 
QALY was stated as £10,057 (Can $23,333). Again, it must be said that the basis of this 
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was a short-term trial but, with a randomised design, having a clearer underlying 
methodology to its analysis than in the other studies. 
 
Glazer et al.
84
 looked specifically at ‘revolving door’ schizophrenic patients and the potential 
effects of depot medication and ‘atypical’ drugs. The study was based on a clinical decision 
analysis model, which was based on a collection of assumptions regarding compliance rates 
and re-hospitalisation rates. The paper compared the three treatment options (depot 
conventionals, oral conventionals and oral ‘atypicals’) under a variety of different scenarios. 
The study used the annual direct treatment costs as the primary outcome measure, 
including drug cost, clinic and case management cost as well as in-patient costs. The model 
used a standard rate of 80% chance of a stable management given patient compliance 
under all three options; this reduces to 15% in non-compliance cases. The key difference 
between the treatment options was in the default compliance rates used: 50% oral 
conventional, 80% depot and 65% oral ‘atypical’.  
 
The conclusion was that depot medication provided a better outcome in all but one of the 
scenarios used. However, under this scenario, in which compliance rates of ‘‘atypicals’ 
increased to 80% and the cost of ‘atypicals’ reduced by 25%, ‘atypicals’ became the 
cheapest option. The quality of evidence presented in this report is limited due to the level of 
assumptions taken and the very much simplified model structure. The authors themselves 
again recognised the need for prospective trial evidence. 
 
In a review of cost-effectiveness studies, Meltzer considered three published studies.
85
 
Meltzer’s conclusion was that clozapine had been found to be clinically superior to 
conventional therapy. He recognised the observed lower costs in treatment-resistant 
patients associated with lower hospitalisation rates, even when including drop-outs from 
clozapine treatment. Overall, he concludes that if drop-outs from clozapine treatment are in 
the range 30-50% and occur within 1-4 months of treatment, then clozapine is likely to be 
cost-effective. Meltzer calls for more focused studies on specific patient groups. 
 
Hargreaves et al. also reviewed the pharmacoeconomics of antipsychotics in the treatment 
of schizophrenia.
86
  This review considered both clozapine and risperidone before widening 
out into a discussion around the inclusion of economic measurement in randomised 
controlled trials. The review comments on the Revicki paper, pointing out the inconclusive 
nature of the report and the fact that follow-up analysis had also failed to provide an 
overwhelming case for clozapine in treatment-resistance. The paper also comments on the 
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modelling work of Davies and Drummond which took the Revicki decision tree into a UK 
setting using a consensus panel. Hargreaves confirms the apparent cost-effectiveness of 
clozapine in this study, but also comments on the sensitivity of this result to slight changes 
in assumptions. 
 
The Hargreaves review also cited a number of studies which considered the cost-
effectiveness of risperidone. All of these were mirror-image studies, which matched the test 
group with a selected group of control patients.
87
  The studies all reported an observed 
reduction in the number of hospitalised days under risperidone and, therefore, implied a 
cost-benefit over standard treatment. However, all fell short of providing a true cost analysis. 
This type of study has a number of associated problems with no true randomisation and no 
blinding within the study design. They are also retrospective by definition. It is very difficult to 
generalise beyond the study in these cases. The review finally considered a retrospective 
study comparing two treatments: risperidone and clozapine. The arms were of a small 
number of patients with a mixture of diagnoses (some of which in the clozapine arm were 
not pure schizophrenia), all of whom had a history of in-patient treatment. Comparisons 
were made with the costs in the year prior to treatment.  
 
In summary, there exists only a limited body of economic information related to ‘atypical’ 
antipsychotics. This is based on a mix of retrospective studies and pharmacoeconomic 
modelling. There is a clear and identified need for more RCT-based analysis with cost- 
effectiveness analysis built into the studies, wherever possible. 
 
Table 20 summarises the cost-effectiveness studies for ‘atypical’ antipsychotics. These are 
primarily focused on clozapine, although there are a limited number relating to risperidone. 
 
Conclusions 
Whilst there appears to be some consideration of cost-effectiveness now reaching the 
published literature, a great deal of this is still focused on the use of clozapine, specifically in 
treatment-resistant patients. Often there is still some confusion over exactly what costs are 
included within the analyses and, generally, the results are difficult to generalise to a wider 
schizophrenic population. A small number of analyses adopt modelling approaches, given 
the lack of focused trial evidence with cost-effectiveness designed as a clear primary 
objective. 
 
From the review of cost-effectiveness evidence, we can draw the following conclusions: 
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 There is suggestive evidence, in the case of clozapine, that there are sufficient cost 
savings from in-patient and other costs to off-set the high direct costs of the drug itself 
and the patient monitoring requirements. 
  
 Although this claim of cost saving has also been made in the case of the other ‘atypical’ 
drugs, there is less evidence for this, and it is certainly a more contentious issue. 
Nevertheless, there may be something in the claims and the NHS ought to be taking 
very seriously the possibility of improving the health state of this group of people at zero, 
or negative net cost. 
  
 The implication of this is that this is a very strong case for some further trial work 
targeted at an economic analysis. A process for starting such analysis is suggested in 
section 3.4 via the use of healthcare modelling.  
 
3.4  Cost-effectiveness Modelling 
 
Given the current lack of cost-effectiveness evidence for the newer ‘atypical’ drugs, from 
either cohort studies or as a product of  clinical randomised controlled trials, we are currently 
faced with the need to adopt other analytical approaches. Without doubt, cohort study data 
will become available once these drugs become more widely used and following enough of 
a time period to observe their real health resource impact. However, until this point is 
reached within what framework should we consider the cost-effectiveness of these drugs? 
 
In the absence of such hard study evidence, a modelling approach would seem to provide 
the most appropriate way to address these real present day prescribing issues and to make 
some level of judgement as to the overall strength of argument for the ‘atypicals’. The use of 
modelling allows the combination of the existing trial evidence with current clinical opinion in 
order to take a view of schizophrenia reflecting the best of current knowledge. A modelling 
approach also enables values and parameters to be challenged, using sensitivity analysis, 
which in turn provides a better appreciation of expected ranges for key outcomes, such as, 
cost-effectiveness. Modelling is also particularly useful in making judgements as to the 
strength of relationship between parameters and to identify those assumptions on which the 
model outcomes rely. Indeed, the Lilly modelling work, described in the review of cost-
effectiveness studies, takes this lead and certainly adds value to the overall debate. 
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In producing this Guidance Note, the authors have considered the type of modelled analysis 
which could be designed. However, they have stopped short of actually conducting any 
model themselves, as the resources required to conduct such an exercise are clearly 
beyond the scope of this document. 
 
The model presented is very much a simplification of the overall treatment management of 
schizophrenia and should be interpreted with the same level of caution and caveats as with 
any other healthcare modelling exercise. The main purpose of the model is to present a 
framework around which to present the known evidence and to facilitate purchasers to begin 
to consider their options. 
 
The model represents three possible treatment pathways for schizophrenic patients, based 
on the three possible scenarios for the use of ‘atypicals’. 
 
 Scenario 1:  Do not use ‘atypicals’ at all in the treatment of schizophrenia (i.e. use 
conventional drugs as first line, with clozapine reserved for treatment 
resistant patients). 
 Scenario 2:  Use ‘atypicals’ as a treatment option after reasonable trial with 
conventional therapy (either 1 or 2 iterations). 
 Scenario 3:  Use ‘atypicals’ in place of conventional drugs as a first line therapy. 
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Table 20  Summary of Cost-effectiveness Studies 
Trial  Design Findings 
Aitchison et 
al. 1997
81
 
Small sample cohort study. 
29 patients. 
Direct/indirect costs. 
Using clozapine, the patient group achieved a £3,768 
annual marginal cost saving - £145 per patient (10% 
reduction).  
Reduced hospitalisation cost £19,740 c.f. £29,072 for 
the cohort. 
Lower levels of unemployment. 
Revicki et al. 
1990
49
 
Retrospective study of 
clozapine vs conventional 
antipsychotics. 
Direct costs. 
Cohort study suggests clozapine reduces costs at the 
end of year 2 by £7,800 ($12,622).   
Davies et al. 
1994
18
 
Model based analysis. 
Used Revicki US study as 
basis. 
Suggested a cost benefit with clozapine of: 
£91 per annum patient cost saving 
£1,333 per patient lifetime saving 
Meltzer et al. 
1993
82
  
Cohort study of treatment 
resistant schizophrenic patients. 
Cost savings observed using clozapine 
Chouinard et 
al. 1996
83
 
Utility analysis. 
Risperidone. 
Based on a multi-centred 
randomised control trial (short 
term) Canadian based. 
Original study showed that risperidone had 
significantly greater efficacy (6-16mg/day) compared 
with haloperidol (20mg/day) using PANSS scale. 
Used QALYs with ratings made by psychiatric nurses 
£10,000 per QALY predicted. 
Glazer et al. 
1996
84
 
Pharmacoeconomic modelling 
based analysis of oral vs depot 
vs ‘atypical’ antipsychotic drugs 
in chronic schizophrenia. 
Costs limited to direct : drugs, 
clinic, monitoring, side-effects 
and inpatient costs. 
Suggests that depot medication can provide cost 
benefits when challenging assumption of compliance 
and hospitalisation rates are taken. Base-case 
suggests :- 
 £5,752 annual cost on oral 
 £4,595 annual cost on depot 
 £7,162 annual cost on ‘atypical’.  
Hargreaves 
et al. 1996
86
 
Review of pharmacoeconomics 
considering clozapine and 
risperidone. 
Identifies the need for more longer-term studies and 
recognised limitations of mirror-studies/ small cohort 
studies- 
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The following diagram shows the structure underpinning the proposed model. 
 
Figure 1 Schematic Decision Tree 
 
The model would need to be populated with data on: 
 drug prescribing  drug costs 
 relapse rates  hospitalisation rates 
 community resource use (Community  resource costs 
 Psychiatric Nurse visits)  suicide rate 
 lengths of stay  treatment switching. 
 drop-out rates  
 
 
It may also prove appropriate to expand the model out to consider treatment switching and 
to reflect patient symptoms. There may also be a case for developing alternative model 
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structures for specific patient groups to reflect the real variety in resource use that can be 
experienced by schizophrenic patients. 
 
As a next step, it may be appropriate for such modelling work to be taken up as part of a 
Regional research programme or even from within a national research co-ordinated 
approach such as the Health Technology Assessment Programme. It would also be worth 
considering the merits of involving the support of the pharmaceutical companies directly, as 
in the Lilly project. However, it is more likely that modelling would be focused on specific 
drugs if this were to be the case. 
 
In summary: 
 A modelling approach appears to be the most appropriate way forward given the early 
stage in ‘atypical’ prescribing;  
 Initial investigations have identified a potential structure to a model and the type of data 
required; 
 Initial investigations have shown that the resources required in the process of gathering 
these data and refining a model structure are significant; 
 The lack of any long-term evidence behind the drugs makes the predicting of benefits, 
and, more importantly, resource impact, difficult and suggests the need for a significant 
amount of clinical opinion gathering; 
 The conducting of such a modelling project lies outside of the scope of a Guidance 
Note; 
 The ways in which  this requirement can be taken forward need to be considered. 
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4.  OPTIONS FOR PURCHASERS AND PROVIDERS 
 
There is insufficient evidence to allow a definitive statement about a best option approach to 
the use of ‘atypical’ neuroleptic medications at the present time.  
 
This is due to: 
 the lack of direct comparisons of ‘atypical’ drugs;  
 the relatively short time period of the existing trials; 
 the lack of detailed and established economic analysis. 
 
It is not possible, therefore, to be confident about the longer-term benefits of these drugs 
and it is also difficult to make comparisons between them, other than in summarising side-
effects. 
 
There are a number of different options which commissioning groups may wish to adopt: 
 
Option 1: Do Nothing  
 
This perpetuates an unsatisfactory and inequitable situation within, and between, health 
authority populations. 
 
Option 2:  Accept fully the use of these drugs for all patients with new onset and 
resistant schizophrenia within the health district.  
 
This assumes that the evidence of the use of these drugs in this way is uncontroversial and 
that evidence of effectiveness in all cases is available, which it is not.  
 
Option 3:  Set a limit on the resources allocated to prescribing, based on an 
incremental  or staged introduction.  
 
This may be achieved by the pragmatic use of modelling processes, which allow for a range 
of priority groups to receive these medications under agreed care protocols. This approach 
should be developed with local discussion.  
 
Newer antipsychotics are more extensively researched and, therefore, safer than 
conventional drugs, indeed chlorpromazine and haloperidol may have difficulty in obtaining 
licences in today’s climate. Therefore, there exists an opportunity to encourage greater use 
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of these new drugs in primary care. Dosage administration and monitoring are all relatively 
straightforward apart from clozapine which will not be considered here. 
 
Current protocols for Nottingham and North Derbyshire Districts are presented at  
Appendix C. 
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5.   DISCUSSION AND CONCLUSIONS 
 
To summarise the key points from the review: 
  
 Evidence of clinical benefit is generally good for all the ‘atypical’ drugs, although still 
short-term in the case of the majority of trials. The majority of evidence relates to the use 
of clozapine in treatment-resistant patients. 
  
 A potential for offsetting drug costs exists from the reduction in hospitalisation costs and 
the avoidance of treatment for relapsed patients. 
  
 There are huge impacts on health authority drug budgets if ‘atypicals’ are to be 
introduced for all schizophrenic patients. 
 
 There remains no clear statement on the cost-effectiveness of the ‘atypicals’, other than 
clozapine, with evidence of cost-effectiveness based on short-term trials of simple 
modelling. 
 
 There remains an issue of exactly which groups are going to be given the ‘atypical’ 
drugs and when.  This question is not really answered from trial evidence alone. 
 
Access to the type of data required to make cost-effectiveness statements remains a real 
problem, with the lack of longer-term studies. 
 
Some patients would rather accept some degree of illness than exposure to certain side-
effects. However, this is only anecdotal and is not a specific area explored within the 
Guidance Note itself.  
 
In terms of further  work: 
 
 There is a need to be more explicit and clearly map out the treatments for schizophrenia, 
with the model structure suggested as the beginning of this process. 
  
 Data gaps need to be clearly identified as a result of the modelling process; we already 
know that much of this will be related to resource use and long-term relapse rates. 
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 Studies are needed to enable ‘missing’ data to be gathered via direct data trawls from 
existing sources or via more primary research. Clinical debate and consensus would 
also play a major role. 
  
 Once data become more readily available, the schizophrenia model can then be re-
populated and evaluated in the light of a revised evidence base. 
  
 Once fully populated, the model can be used to conduct a realistic cost-effectiveness 
analysis. 
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6.   USE OF CURRENT ‘ATYPICAL’ ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: SUMMARY MATRIX 
 
PATIENT GROUP PATIENT CRITERIA 
(GUIDELINES NOT PROTOCOLS) 
ESTIMATED 
FUTURE 
ACTIVITY 
OPPORTUNITY 
FOR COST 
SAVING 
AUDIT POINTS EFFECTS THAT COULD BE 
EXPECTED IN RELATION 
TO STARTING POINT 
 
COST-EFFECTIVENESS 
 
Use of ‘atypicals’ 
(excluding 
clozapine) in 
Multiple Relapse + 
First Episode 
schizophrenic 
patients. 
 
 
 
 
 
 
 
 
 
These are patients who: 
 do not respond clinically to 
conventional treatment, or  
 remain responsive to first line 
treatments, but who may have 
problems with side-effects of 
conventional treatment.  
Together this is estimated at 70% of 
patients, with the remaining 30% 
maintained on conventional drugs. 
 
 
Within a ‘typical’ 
district a six 
month prevalence 
of 900-1,000 
patients fitting this 
criteria would be 
expected. 
 
Annual increase 
in drug cost 
estimated at £1.8 
million from 
around £200-
300,000 on 
conventionals. 
 
Potential to 
increase the time 
between 
subsequent 
relapse, lowering 
hospitalisation 
costs. 
Also indications 
that problems 
related to EPSE 
are reduced 
significantly. 
 
Information would 
need to be 
compiled on: 
 compliance 
 relapse rates 
 drop-out 
 side-effects 
 resource use 
 admission 
rates 
 suicide 
attempts. 
 
 
An effect on the negative 
symptoms of the illness. 
 
At least an equal efficacy 
related to the positive 
symptoms. 
 
No information on cost-
effectiveness currently available. 
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APPENDIX A   TRIAL SUMMARIES 
Song Meta Analysis: Double-blind, randomised clinical trials: risperidone versus other neuroleptics
60  
Study Antipsychotic drugs and 
daily dose 
No. of 
patients 
Duration 
(weeks) 
Diagnoses Baseline mean 
scores 
Length of 
current 
hospitalisatio
n (weeks) 
Mean 
length of 
illness 
(years) 
Marder et al. (1994)
66
 Risperidone 2, 6, 10, 16mg 
Haloperidol 20mg  
placebo 
 256 
 66 
 66 
 8 Chronic (DSM-III-R), 
PANSS total score  
60-120 
PANSS: 92.1 
dBPRS: 53.7 
 29.7  15.8 
Chouinard et al. (1993)
65
 Risperidone 2, 6, 10, 16mg 
Haloperidol 20mg 
Placebo 
 92 
 21 
 22 
 8 Chronic (DSM-III-R), 
PANSS total score 
60-120 
PANSS: 94.2 
dBPRS 54.4 
 100.5  16 
Peuskens. (1995)
67
 Risperidone 1, 4, 8, 12, 16mg 
Haloperidol 10mg 
 1136 
 226 
 8 Chronic (DSM-III-R) 
PANSS total score 
60-120 
PANSS: 89.7 
dBPRS: 48.7 
 17.8  15.3 
Blin et al. (1995)
62
 Risperidone 4-12mg 
Haloperidol 4-12mg 
Methotrimprazine 50-150mg 
 21 
 20 
 21 
 4 (DSM-III-R) with an 
acute exacerbation and 
psychotic anxiety 
PANSS: 120.5 
dBPRS: NA 
 NA  NA 
Hoyberg et al. (1993)
88
 Risperidone 5-15mg 
Perphenazine 16-48mg 
 55 
 52 
 8 Chronic patients with 
acute exacerbation  
(DSM-III-R) 
PANSS: 94:5 
dBPRS: 53 
 NA  NA 
Claus et al. (1992)
89
 Risperidone 1-10mg 
Haloperidol 1-10mg 
 22 
 22 
 12 Chronic patients (DSM-
III) 
PANSS : 86.2 
dBPRS : NA 
 NA  14.1 
Min et al. (1993)
63
 Risperidone 5-10mg 
Haloperidol 5-10mg 
 16 
 19 
 8 Chronic (DSM-III-R), 
PANSS total score 
60-120 
 
PANSS: 89.9 
dBPRS: 50.9 
 22  10.6 
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Huttenen et al. (1995)
90
 Risperidone 4-10mg 
Zuclopenthixol 20-50mg 
 48 
 50 
 6 Chronic (DSM-III-
R),with acute psychotic 
symptoms 
PANSS: 93.3 
dBPRS: 53.9 
 0.9  12.5 
Ceskova et al. (1993)
91
 Risperidone 2.5-9.5mg  31  8 Schizophrenia (ICD-() 
and schizoaffective 
psychosis 
BPRS: 44.3  23.8  10.4 
Mesotten et al. (1991)
64
   Risperidone 2-10mg 
Haloperidol 2-10mg 
 28 
 32 
 8 Schizophrenic, 
paranoid, other 
psychotic patients 
(DSM-III) 
BPRS: 50.6  NA  >5.8 
Borison et al. (1992)
 92
 Risperidone 2-10mg 
Haloperidol 4-20mg  
Placebo 
 53 
 53 
 54 
 6 (DSM-III-R) 
BPRS >30 
BPRS: 51.3  NA  15.1 
 
PANSS: Positive and Negative Symptom Rating Scale 
BPRS: Brief Psychiatric Rating Scale 
dBPRS: PANSS-derived BPRS 
DSM-III: Diagnostic and Statistical Manual of Mental Disorder (3rd edn), the American Psychiatric Association (1980). 
DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders (3rd edn - Revised), the American Psychiatric Association (1987) 
ICD-9: International Classification of Diseases (9th revision) 
NA: not available. 
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Risperidone Trial Data: Wessex Report No 48 
Randomised Double-Blind Studies of Risperidone 
Author Study Population Design
a
 (all double-blind 
studies) 
Duration 
weeks 
No. 
patients 
Main efficacy 
assessment
b
 
End-point improvement  
(R versus H or M or P or C) 
 
      Overall  EPSE 
Borison et al., 
1991
Error! Bookmark not 
defined.
 
 R vs. H vs. PL, 1-10mg 6  160 BPRS Tendency to 
greater effect 
Lesser effect 
(p<0.05) 
Borison et al., 1992
92
 DSM-III-R schizophrenics minimum score 30 
on BPRS 
Titration to effect: r 2-
10mg/day vs. H4-20mg/ day 
vs.pl 
6  36 BPRS 
SANS 
Tendency to 
greater effect 
Lesser effect 
(p<0.05) 
Chouinard et al., 
1993
65
  
DSM-III-R chronic schizophrenics, PANSS 
scores 60-120 
Fixed dose: r 2, 6, 10 or 
16mg/day vs. H 30mg/day 
vs. pl 
8  135 PANSS Identical or 
greater effect 
Lesser or 
identical effect 
Marder et al., 1991  DSM-III-R chronic schizophrenics, PANSS 
score 60-120 
Fixed dose: r 2,6,10 or 
16mg/day vs. H 20mg/ day 
vs.pl 
8  523 PANSS Greater effect 
(p>0.05) 
Lesser effect 
(p<0.05) 
Marder et al., 1994
66
  R vs. H vs. PL, 2-16mg 8  388 PANSS Identical or 
greater effect 
Tendency to 
lesser effect 
Peuskens et al., 
1992
67
 
DSM-III-R chronic schizophrenics, PANSS 
scores 60-120 
Fixed dose: R 1, 4, 8, 12 or 
16mg/day vs. H 10mg/ day 
vs pl. 
 
8  1362 PANSS Identical or 
greater effect 
Lesser or 
similar effect 
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Risperidone vs. Haloperidol 
Mesotten 1991 
64
  H vs. R 2-20mg 8  60 BPRS Similar effect Tendency to 
lesser effect 
Claus et al., 1992 
89
 DSM_III-R chronic schizophrenics, previously 
optimised on last treatment 
Titrated to effect in first 6 
weeks: H 2-20mg/ day vs. R 
2-20mg/ day; dose 
maintained for last 6 weeks 
12  44 PANSS 
SADS-C 
Tendency to 
greater effect 
Identical 
Risperidone vs. Haloperidol vs. Methtrimaprizine 
Tatossian et al., 1991 DSM-III-R acute schizophrenics Titrated to effect: R 4-
12mg/day vs. H 4-12 
mg/day vs. M 50-
150mg/day. 
4  62 PANSS Greater effect 
(p>0.05) than 
both 
Similar to M; M 
lesser effect 
than H 
(p<0.05) 
Risperidone vs. Haloperidol 
Remvig, 1991  R vs. P, 5-15mg 8  107 PANSS Greater effect 
(p<0.05) than 
both 
Similar effect 
Hoyberg et al., 1993
88
 Acute exacerbations in chronic DMS-III-R 
schizophrenics 
Double-blind dose titrated to 
effect in first 4 weeks; R 5-
15mg/day vs. P 16-48 
mg/day; dose maintained 
for the final 4 weeks 
8  107 PANSS Tendency to 
greater effect 
Identical 
 
a
 =  R: risperidone, H: haloperidol, PL: placebo, M: methtrimaprizine, P: perphanzine, C; clozapine 
b
= BPRS: Brief Psychiatric Rating Scale, SANS: Scale for Assessment of Negative Symptoms, PANSS: Positive and Negative Syndrome  Scale, SADS-C: Schedule for 
 Affective Disorders and Schizophrenia - Change Version. 
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APPENDIX B  ICD 10 CLASSIFICATION OF SCHIZOPHRENIA 
 
Code  Disorder 
F20  Schizophrenia 
F22  Persistent delusional disorder 
F23  Acute and transient psychotic disorder 
F25  Schizoaffective disorders 
F30  Manic episode 
F31  Bipolar affective disorder 
 
Source :  WHO ICD10 Classification System of Mental Health and Behavioural Disorder 
  69 
APPENDIX C  CURRENT PROTOCOLS FOR ‘ATYPICAL’ PRESCRIBING 
 
The following presents two examples of suggested treatment protocols for the use of ‘atypical’ 
antipsychotics. These protocols have both been developed locally by clinicians within the North 
Derbyshire and Nottingham Districts. As such, it is understood that they are not a statement of 
health authority policy, but do provide useful input into the development of such protocols. 
 
North Derbyshire 
 
PROTOCOL FOR USE OF ‘ATYPICAL’ NEUROLEPTICS 
Background 
It is tempting to reserve the use of these drugs for cases where all other treatments have failed. 
However they are not licensed for use in treatment resistance and logic dictates that they are much 
more likely to benefit patients at an earlier, less intractable, stage of illness. Their price and relative 
novelty would suggest that they could not currently be recommended as first line treatment. The 
following protocol suggests a way that the drugs can be apportioned sensibly whilst monitoring 
reasons for use and measuring effectiveness in the local population. 
 
Protocol 
- Diagnosis of Schizophrenia 
and 
- Treatment with accepted therapeutic dose of standard neuroleptic for minimum of six weeks  
and 
- Lack of response or inability to tolerate drug 
- Quantify with HONOS/BPRS/AIMS/GAF then 
- Use Risperidone/Olanzapine/Sertindole at therapeutic dose for minimum of six weeks 
- Register patient on database 
- Repeat database 
- Repeat baseline measures after six weeks 
 
Note: 
HONOS - a scale for measuring the overall outcome of patients with psychiatric illness. 
BPRS     - a measure of the severity of psychotic symptoms. 
AIMS     - a measure of the extra pyramidal symptoms produced by neuroleptics. 
GAF       - a global measure of overall functioning. 
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Nottingham 
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APPENDIX D ASSESSMENT OF OTHER NEW ANTIPSYCHOTIC DRUGS 
The following information was provided by the Trent Drug Information Service through ADIs R&D 
Insight (1998). 
The tables provide further detail on other new ‘atypical’ antipsychotic drugs which are beginning to 
be marketed (Amisulpride; Quetiapine; Ziprasidone; Zotepine).  
 
Approved name Amisulpride 
Manufacturer Lorex 
Status in UK Marketed November 1997 
Pharmacology 
Indications/use 
Dopamine D2/D3 antagonist 
Licensed in UK for treatment of acute and chronic schizophrenic disorders in which 
positive or negative symptoms are prominent 
Cost/month £60-£120 (400-800mg daily) for acute episodes 
£8-£45 (50-300mg) for predominantly negative symptoms 
Clinical evidence  A bell-shaped dose-response curve was observed with amisulpride 100-1200 mg/day 
in a 4-week dose-ranging study, which used haloperidol 16 mg/day as a positive 
control, and involved 317 patients with acute exacerbation of schizophrenia. 
Amisulpride 400 and 800 mg/day were the most effective doses for positive symptoms. 
A similar, but non-significant effect, was seen with negative symptoms [1]. 
Amisulpride was at least as effective as haloperidol in the treatment of acute 
exacerbations of schizophrenia, and was more effective in the treatment of negative 
symptoms, in a multicentre, double-blind European study in which 191 patients were 
randomised to treatment with amisulpride 800 mg/day or haloperidol 20 mg/day bid for 
6 weeks [2]. 
Equivalent antipsychotic effects of amisulpride (1000 mg/day) and flupenthixol 
(25 mg/day) were observed in a 6-week, randomised, double-blind trial involving 132 
patients with acute schizophrenia with predominantly positive symptomatology. There 
was no difference between treatments in the time course of improvement [3]. 
Adverse effects Agitation, amenorrhoea, anxiety, extrapyramidal disorders, galactorrhoea, sleep 
disorders 
 
 
References 
1 Puech A et al.. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: 
a dose-ranging study vs. haloperidol. Acta Psychiatrica Scandinavica 1998; 98: 65-72. 
2 Möller HJ et al.. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with 
haloperidol. Psychopharmacology 1997; 132: 396-401. 
3 Wetzel H et al.. Amisulpride versus flupentixol in schizophrenia with predominantly positive 
symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-
/D2-like antagonist. Psychopharmacology 1998; 137: 223-232. 
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Approved name Quetiapine 
Manufacturer Zeneca 
Status in UK Marketed October 1997 
Pharmacology 
Indications/use 
Dopamine D2/5HT2 antagonist 
Indicated for the treatment of schizophrenia (no qualifications) 
Cost/month £113-142 (300-450mg daily) 
Clinical evidence  In a large phase II double-blind study, 106 patients with chronic or subchronic 
schizophrenia received at least 1 week of either quetiapine (mean dosage 307 mg/day) 
or placebo. Quetiapine was more effective than placebo in treating psychotic symptoms 
in patients. [4]. In a double-blind multicentre study, 361 patients with an acute 
exacerbation of chronic or subchronic schizophrenia were randomised to receive 
quetiapine 75, 150, 300, 600 or 750 mg/day, haloperidol 12 mg/day or placebo for 6 
weeks. There were no significant differences between quetiapine and haloperidol in 
any of the efficacy parameters [5].  
In a phase III study of 618 patients with schizophrenia, the efficacy and tolerability of 
quietapine at 3 different dosages and dosing regimens (50-450 mg/day bid-tid) for 6 
weeks was evaluated. A significantly greater improvement in various rating scores was 
found after quetiapine 225mg bid compared with 25mg bid. Quetiapine 150mg tid was 
significantly superior to 25mg bid with respect to BPRS total score. The 225mg bid and 
the 150mg tid dosage groups were not significantly different with respect to any efficacy 
measure [6]. 
In a multicentre US and European study, 286 patients with acute exacerbation of 
chronic or subchronic schizophrenia received PO high-dose quetiapine (maximum daily 
dose 750mg; n = 96), low-dose quetiapine (maximum daily dose 250mg; 94), or 
placebo (96), for 42 days. High-dose quetiapine therapy (mean daily dose 360mg) 
resulted in significant improvements rating scores compared with placebo. The 
significant changes in the BPRS positive-symptom cluster score showed the consistent 
effect of quetiapine in reducing positive symptoms, but its effect on negative symptoms 
was less consistent [7]. 
201 patients with an acute exacerbation of chronic or subchronic schizophrenia or 
schizophreniform disorder were randomised to receive quetiapine or chlorpromazine 
(titrated up to a maximum dosage of 750 mg/day) for 6 weeks. Both treatments were 
associated with marked improvements in BPRS total score and CGI Severity of Illness 
score, although the clinical significance of some measures were variable [8]. 
Adverse effects Agitation, amenorrhoea, anxiety, dizziness, drowsiness, dry mouth, extrapyramidal 
disorders, galactorrhoea, headache, sleep disorders, tachycardia. Cataract potential in 
animals has not been confirmed in humans. 
 
 
References 
4 Borison Riet al.. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-
controlled trial in patients with schizophrenia. Journal of Clinical Psychopharmacology 1996; 16: 158-169. 
5 Arvanitis LA et al.. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of 
schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry 1997; 42: 233-246. 
6 King Djet al.. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of 
schizophrenia. Psychopharmacology 1998; 137: 139-146. 
7 Small JG et al.. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison 
with placebo. Archives of General Psychiatry 1997; 54: 549-557. 
8 Peuskens J and Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of 
schizophrenia. Acta Psychiatrica Scandinavica 1997; 96: 265-273. 
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Approved name Ziprasidone 
Manufacturer Pfizer 
Status in UK Phase III trials in USA. FDA approval withheld pending further data. 
Earliest UK marketing 2000/1 
Pharmacology 
Indications/use 
Dopamine D2/5HT2 antagonist 
Treament of schizophrenia (qualifications unknown) 
Cost/month Unknown 
Clinical evidence  In a multicentre, double-blind study which enrolled 302 patients with schizophrenia, a 6-
week treatment with ziprasidone 80 or 160 mg/day significantly improved positve and 
negative symptom and other rating scores [9]. Another double-blind study compared 
the efficacy of ziprasidone with that of placebo in the treatment of 139 patients with 
schizophrenia or schizoaffective disorders. After a 28-day treatment period with 
ziprasidone 40 or 120 mg/day, a significantly larger number of ziprasidone 120 mg/day 
recipients (48.8%), compared with ziprasidone 40 mg/day (37.2%) or placebo 
recipients (25.5%) experienced ³30% reduction in BPRS total score, or had Clinical 
Global Impression (CGI) severity scores of 1-2 (33.3%, 20.9% and 12.8%, respectively) 
[10]. In a preliminary report from a randomised, double-blind, placebo-controlled study 
involving 294 patients with schizophrenia reduced the rate of psychotic relapse over a 
1-year period (6% relapse rate vs 35% placebo)  and demonstrated a continuing 
improvement in negative symptoms and functioning over the course of the study  
The IM formulation of ziprasidone produced marked improvement in psychopathology 
and symptoms of psychomotor agitation by day 3 in a pilot study involving 12 acutely ill 
patients with schizophrenia. These patients received fixed doses of IM ziprasidone 20-
80 mg/day for 3 days, followed by PO ziprasidone on days 4 and 5[12]. 
Adverse effects Anxiety, agitation, dizziness, extrapyramidal symptoms, GI disorders, headache, skin 
rashes, sleep disorders,  
References 
9 Small JG et al.. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind 
comparison with placebo. Archives of General Psychiatry 1997; 54: 549-557. 
10 Small JG et al.. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind 
comparison with placebo. Archives of General Psychiatry 1997; 54: 549-557. 
11 Goff DC et al.. An exploratory haloperidol-controlled dose-finding study of ziprasidone in 
hospitalized patients with schizophrenia or schizoaffective disorder. Journal of Clinical 
Psychopharmacology 1998; 18: 296-304. 
12 Elwood W. Atypical antipsychotics lining up to help in schizophrenia. Inpharma 1110: 13-15, 25 
Oct 1997. 
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Approved name Zotepine 
Manufacturer Orion Pharma 
Status in UK Marketed November 1998 
Pharmacology 
Indications/use 
Dopamine D2/D3 antagonist:Noradrenaline reuptake inhibitor 
Treatment of positive and negative symptoms in schizophrenia 
Cost/month £35-£99 (75-300mg daily) 
Clinical evidence  In a placebo-controlled study comparing zotepine (150-300mg) to chlorpromazine (300-
600mg) it was demonstrated that zotepine was clinically and statistically superior to 
chlorpromazine in symptom control, and was also associated with a lower risk of 
extrapyramidal symptoms [13]. A study in patients with acute exacerbation of chronic 
schizophrenia which compared zotepine (150-300mg) to haloperidol (10-20mg) 
demonstrated that zotepine was as effective as haloperidol in improving the positive 
symptoms of schizophrenia, significantly more effective on the negative symptoms, and 
induced significantly less extrapyramidal symptoms and treatment-emergent adverse 
events [14]. 
Adverse effects Asthma, dizziness, dry mouth, sleep disorders, tachycardia, weight increase. 
References 
13 Cooper SJ et al.. Zotepine in acute exacerbation of schizophrenia: a comparison versus 
chlorpromazine and placebo. European Neuropsychopharmacology 1996; 6 (Suppl. 3): 148. 
14 Petit M et al.. A comparison of an atypical and typical antipsychotic, zotepine versus 
haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind 
trial. Psychopharmacology Bulletin 1996; 32: 81-87. 
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